

# CITATION REPORT

List of articles citing

## Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

DOI: 10.1056/nejmoa1709118

New England Journal of Medicine, 2017, 377, 1319-1330.

**Source:** <https://exaly.com/paper-pdf/66949653/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #    | Paper   | IF   | Citations |
|------|---|------|-----------|
| 1492 | Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <b>2017</b> , 70, 1760-1776  |      | 100       |
| 1491 | [Coronary thrombosis: Physiopathology and treatment in the era of tailored medicine]. <b>2017</b> , 66, 373-379   |      |           |
| 1490 | Review of article: Rivaroxaban with or without aspirin in stable cardiovascular disease. Eikelboom JW, Connolly SJ, Bosch J, et al. for the COMPASS investigators. <b>2017</b> , 35, 221-223                              |      | 3         |
| 1489 | [Focused update on dual antiplatelet treatment : ESC guidelines 2017]. <b>2017</b> , 42, 739-745  |      | 3         |
| 1488 | An Important Step for Thrombocardiology. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1387-1388  | 59.2 | 16        |
| 1487 | Antithrombotic therapy: COMPASS points to low-dose rivaroxaban and aspirin for secondary prevention. <b>2017</b> , 14, 630-631  |      | 2         |
| 1486 | Scientific surgery. <b>2017</b> , 104, 1894-1894  |      |           |
| 1485 | [ESC guidelines 2017 on peripheral arterial diseases : Summary of the most important recommendations and innovations]. <b>2017</b> , 42, 721-727  |      | 4         |
| 1484 | [ESC guidelines 2017 : What is new and what is of particular importance?]. <b>2017</b> , 42, 713-714  |      |           |
| 1483 | The role of oral anticoagulant therapy in patients with acute coronary syndrome. <b>2017</b> , 8, 353-366   |      | 13        |
| 1482 | [Involvement of thrombophilia in coronary thrombosis]. <b>2017</b> , 66, 365-372  |      |           |
| 1481 | Antikoagulation bei perkutaner Koronarintervention Update 2017. <b>2017</b> , 13, 339-354   |      |           |
| 1480 | Rationale and design of the long-Term risk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. <b>2017</b> , 40, 1197-1204 |      | 7         |
| 1479 | Milestone 14: COMPASS-guided secondary prevention. <b>2017</b> ,  |      |           |
| 1478 | Frontiers of Prevention: Pollution, Infection, Cognitive Function and Frailty. <b>2017</b> , 38, 3179-3182  |      | 2         |
| 1477 | Trials of Patent Foramen Ovale Closure. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2599-2600   | 59.2 | 4         |
| 1476 | Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. <b>2017</b> , 113, e61-e63  |      | 3         |

|      |  |    |
|------|--|----|
| 1475 | What big data could achieve in Scotland. <b>2017</b> , 47, 396   |    |
| 1474 | Lipidomik identifiziert Ceramide als neue kardiovaskuläre Risikomarker. <b>2017</b> , 17, 56-61  |    |
| 1473 | Kombination toppt ASS-Monotherapie. <b>2017</b> , 19, 23-23  |    |
| 1472 | European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017. <b>2017</b> , 81, 1758-1763   | 2  |
| 1471 | Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation. <b>2018</b> , 199, 137-143 | 3  |
| 1470 | Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. <b>2018</b> , 3, 231-241                         | 96 |
| 1469 | Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice. <b>2018</b> , 20, 978-988  | 5  |
| 1468 | Back to the Future. <b>2018</b> , 55, 453-454  | 0  |
| 1467 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. <b>2018</b> , 20, 15   | 5  |
| 1466 | Network analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targets. <b>2018</b> , 8, 3434  | 31 |
| 1465 | Rivaroxaban in peripheral artery disease: The new kid on the block?. <b>2018</b> , 67, 985-986   | 4  |
| 1464 | Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection. <b>2018</b> , 45, 423-431  | 4  |
| 1463 | Marcumar-Therapie bei infrainguinalen Venenbypassen: Pro. <b>2018</b> , 23, 69-72  |    |
| 1462 | Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <b>2018</b> , 39, 1672-1686f  | 59 |
| 1461 | Peripheral arterial disease guidelines: the Cinderella of cardiovascular medicine gets the attention it deserves. <b>2018</b> , 39, 717-719  |    |
| 1460 | Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <b>2018</b> , 200, 102-109   | 5  |
| 1459 | Acute Coronary Syndromes. <b>2018</b> , 197-216  | 0  |
| 1458 | Direct Oral Anticoagulants. <b>2018</b> , 87-103   |    |

|      |  |        |
|------|--|--------|
| 1457 | Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. <b>2018</b> , 34, 1945-1957  | 2      |
| 1456 | Optimal pharmacological therapy in ST-elevation myocardial infarction-a review : A review of antithrombotic therapies in STEMI. <b>2018</b> , 26, 296-310  | 10     |
| 1455 | Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice. <b>2018</b> , 138, 1706-1719  | 41     |
| 1454 | Coagulation Factors in Ischemic Heart Disease: Answers From a Mendelian Randomization Study Inspire Further Questions. <b>2018</b> , 11, e002045   | 1      |
| 1453 | Casting NETs to predict cardiovascular outcomes. <b>2018</b> , 25, 759-761   | 2      |
| 1452 | Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding. <b>2018</b> , 23, 191-192 | 0      |
| 1451 | Novedades en el tratamiento médico de la cardiopatía isquémica estable. <b>2018</b> , 53, 101-105  | 1      |
| 1450 | Incremental prognostic value of coronary and systemic atherosclerosis after myocardial infarction. <b>2018</b> , 261, 6-11   | 9      |
| 1449 | Physicians Addicted to Prescribing Aspirin-a Disorder Of Cardiologists (PAPA-DOC) Syndrome: The Headache of Nonevidence-Based Medicine for Ischemic Heart Disease?. <b>2018</b> , 6, 168-171                           | 3      |
| 1448 | Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <b>2018</b> , 34, 295-302                                    | 17     |
| 1447 | Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <b>2018</b> , 60, 524-530   | 4      |
| 1446 | Frontiers in cardiovascular prevention. <b>2018</b> , 39, 329-332  | 1      |
| 1445 | Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis. <b>2018</b> , 3, 234-241                                | 30     |
| 1444 | Recent Developments in Sex-Related Differences in Presentation, Prognosis, and Management of Coronary Artery Disease. <b>2018</b> , 34, 390-399  | 15     |
| 1443 | Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. <b>2018</b> , 38, 726-732  | 11     |
| 1442 | Recent Approaches to Improve Medication Adherence in Patients with Coronary Heart Disease: Progress Towards a Learning Healthcare System. <b>2018</b> , 20, 5  | 16     |
| 1441 | Rivaroxaban in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 397-398  | 59.2 3 |
| 1440 | Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. <b>2018</b> , 71, 352-362  | 15     |

|      |   |     |
|------|---|-----|
| 1439 | The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation. <b>2018</b> , 39, 474-476  | 2   |
| 1438 | [Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]. <b>2018</b> , 59, 288-303  | 0   |
| 1437 | P2Y receptor inhibitors: an evolution in drug design to prevent arterial thrombosis. <b>2018</b> , 14, 303-315  | 14  |
| 1436 | A COMPASS to REACH the right patients with thrombocardiology: benefits, risks, and future of the new concept. <b>2018</b> , 39, 758-761   | 4   |
| 1435 | Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <b>2018</b> , 199, 83-91 | 71  |
| 1434 | Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <b>2018</b> , 71, 727-735   | 18  |
| 1433 | Rivaroxaban with or without aspirin for prevention of cardiovascular disease. <b>2018</b> , 29, 361-365   |     |
| 1432 | Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. <b>2018</b> , 17, 251-258                                 | 1   |
| 1431 | Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury. <b>2018</b> , 820, 222-228  | 17  |
| 1430 | 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants. <b>2018</b> , 38, 304-310  | 23  |
| 1429 | Canakinumab for secondary prevention of atherosclerotic disease. <b>2018</b> , 18, 215-220  | 7   |
| 1428 | Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective?. <b>2018</b> , 15, 119-126   | 22  |
| 1427 | [Platelet inhibition in elderly patients]. <b>2018</b> , 43, 222-229  | 0   |
| 1426 | Direct oral anticoagulants: An update. <b>2018</b> , 151, 198-206   | 15  |
| 1425 | 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <b>2018</b> , 34, 214-233                      | 125 |
| 1424 | Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. <b>2018</b> , 60, 514-523   | 7   |
| 1423 | Panvascular disease - Epidemiology and prevention. <b>2018</b> , 60, e3-e8  | 2   |
| 1422 | Current and future antiplatelet therapies: emphasis on preserving haemostasis. <b>2018</b> , 15, 181-191  | 129 |

|      |   |    |
|------|---|----|
| 1421 | Antithrombotic therapy in 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease. <b>2018</b> , 15, 71-72   | 3  |
| 1420 | The year in cardiology 2017: coronary interventions. <b>2018</b> , 39, 914-924  | 1  |
| 1419 | External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <b>2018</b> , 39, 750-757a   | 56 |
| 1418 | The year in cardiology 2017: prevention. <b>2018</b> , 39, 345-353  | 3  |
| 1417 | Selection of the Best of 2017 in Ischemic Heart Disease. <b>2018</b> , 71, 124-125  |    |
| 1416 | Strategies for the Prevention of Coronary Artery Disease Complications: Can We Do Better?. <b>2018</b> , 131, 1003-1009   | 4  |
| 1415 | Antithrombotic drugs in cardiovascular medicine: a year in review. <b>2018</b> , 33, 369-374  | 2  |
| 1414 | Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5-Year CORONOR Registry. <b>2018</b> , 7,  | 4  |
| 1413 | COMPASS-Studie weist neue Wege. <b>2018</b> , 20, 14-14   |    |
| 1412 | Optimal duration of dual antiplatelet therapy for coronary artery disease. <b>2018</b> , 26, 321-333  | 6  |
| 1411 | Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. <b>2018</b> , 265, 108-112 | 19 |
| 1410 | A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. <b>2018</b> , 16, 1296-1306  | 24 |
| 1409 | Antithrombotic Therapy in Acute Coronary Syndrome: Striking a Happy Medium. <b>2018</b> , 71, 782-786   | 2  |
| 1408 | The coagulation system in atherothrombosis: Implications for new therapeutic strategies. <b>2018</b> , 2, 188-198   | 25 |
| 1407 | Coronary Artery Disease in Patients 80 Years of Age. <b>2018</b> , 71, 2015-2040  | 81 |
| 1406 | Arterial thrombosis and cancer. <b>2018</b> , 164 Suppl 1, S23-S28  | 32 |
| 1405 | Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction. <b>2018</b> , 24, 1088-1094  | 6  |
| 1404 | [Direct oral anticoagulants (DOACs): A necessary focus]. <b>2018</b> , 43, 198-205  |    |

|      |   |      |
|------|---|------|
| 1403 | Non-Vitamin K Antagonist Preferred in Patients With Nonvalvular Atrial Fibrillation and Indication for Aspirin Therapy. <b>2018</b> , 137, 1130-1131                                    |      |
| 1402 | Influence of vitamin K antagonists and direct oral anticoagulation on coronary artery disease: A CTA analysis. <b>2018</b> , 260, 11-15   | 19   |
| 1401 | Cardioembolic stroke: everything has changed. <b>2018</b> , 3, 76-83  | 21   |
| 1400 | Recent major advances in cardiovascular pharmacotherapy. <b>2018</b> , 74, 853-862  | 3    |
| 1399 | Atrial Fibrillation, Past and Future: From a Stroke Non-Entity to an Over-Targeted Cause. <b>2018</b> , 45, 149-153   | 5    |
| 1398 | Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. <b>2018</b> , 71, 2306-2315  | 173  |
| 1397 | Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. <b>2018</b> , 25, 158-168           | 45   |
| 1396 | Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome. <b>2018</b> , 3, 784-793  | 16   |
| 1395 | Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies. <b>2018</b> , 29, 246-258   | 5    |
| 1394 | The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation. <b>2018</b> , 261, 78-83  | 18   |
| 1393 | Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. <b>2018</b> , 20, B21-B28  | 1    |
| 1392 | Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes. <b>2018</b> , 39, 1086-1088   | 4    |
| 1391 | Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. <b>2018</b> , 45, 578-587             |      |
| 1390 | The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <b>2018</b> , 39, 1330-1393 | 1094 |
| 1389 | Biomarkers in stable coronary artery disease. <b>2018</b> , 196, 82-96  | 23   |
| 1388 | Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome. <b>2018</b> , 121, 301-307      | 13   |
| 1387 | The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <b>2018</b> , 11, 5-12                              | 14   |
| 1386 | Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <b>2018</b> , 137, 684-692                   | 10   |

|      |   |     |
|------|---|-----|
| 1385 | Why women are not small men. <b>2018</b> , 107, A3-A4   | 3   |
| 1384 | Anti-inflammatory agents in peripheral arterial disease. <b>2018</b> , 39, 1-8  | 16  |
| 1383 | Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. <b>2018</b> , 19, 516-520  | 11  |
| 1382 | Selección de lo mejor del año 2017 en cardiopatía isquémica. <b>2018</b> , 71, 124-125  |     |
| 1381 | Bleeding in advanced CKD patients on antithrombotic medication - A critical appraisal. <b>2018</b> , 129, 535-543   | 10  |
| 1380 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <b>2018</b> , 391, 205-218   | 204 |
| 1379 | Antithrombotic therapy in peripheral artery disease. <b>2018</b> , 391, 183-184   | 4   |
| 1378 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <b>2018</b> , 391, 219-229  | 414 |
| 1377 | Secondary prevention shifts into second gear. <b>2018</b> , 391, 181-182  | 1   |
| 1376 | Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). <b>2018</b> , 137, 338-350 | 348 |
| 1375 | Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?. <b>2018</b> , 13, 93-98  | 3   |
| 1374 | Cardiovascular events after discontinuation of low-dose aspirin. <b>2018</b> , 10, 75-78  |     |
| 1373 | Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study. <b>2018</b> , 13, 115-118   | 4   |
| 1372 | A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge. <b>2018</b> , 10, 523-526   | 4   |
| 1371 | Vitamin K Antagonists, Non-Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation. <b>2018</b> , 2, e391-e398  | 14  |
| 1370 | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion. <b>2018</b> , 14, 272-283  | 3   |
| 1369 | Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity. <b>2018</b> , 2, e173-e181   | 6   |
| 1368 | Combining anticoagulation and antiplatelet drugs in coronary artery disease. <b>2018</b> , 41, 111-115  | 4   |



1367 New data from two CV trials result in one win, one loss. **2018**, 24, 22

1366 Multiple protein disulfide isomerases support thrombosis. **2018**, 25, 395-402

20

1365 The Role of Double and Triple Therapy with Direct Oral Anticoagulants in Coronary Artery Disease, Peripheral Artery Disease, and Stroke. **2018**, 40, 1907-1917.e3

3

1364 Search for a Panacea Continues. **2018**, 49, 3118-3119

1363 ACC/AHA Versus ESC Guidelines for Diagnosis and Management of Peripheral Artery Disease: JACC Guideline Comparison. **2018**, 72, 2789-2801

29

1362 Update: The role of antiplatelet medications in cardiovascular patients. **2018**, 36, 218-221

1361 Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. **2018**, 14, 443-453

3

1360 The Net Clinical Benefit of Rivaroxaban for Patients With Acute Coronary Syndrome. **2018**, 72, 2411-2412

1359 Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. **2018**, 72, 2297-2305

24

1358 The Potential for Troponin to Inform Prognosis in Patients With Stable Coronary Artery Disease. **2018**, 169, 808-809

3

1357 Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. **2018**, 7, e009217

34

1356 An evaluation of warfarin use at an urban district-level hospital in KwaZulu-Natal Province, South Africa. **2018**, 108, 1046-1050

4

1355 Use of oral anticoagulants in complex clinical situations with atrial fibrillation. **2018**, 150 Suppl 1, 8-24

2

1354 Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. **2018**, 72, 3274-3284

31

1353 Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. **2018**, 1, e185239

40

1352 Updates on Prevention of Cardioembolic Strokes. **2018**, 20, 180-196

21

1351 Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. **2018**, 72, 2886-2903

33

1350 ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. **2018**, 72, 2915-2931

163

|      |   |        |
|------|---|--------|
| 1349 | [Update ESC-Guideline 2017: Focus on PAD]. <b>2018</b> , 143, 1455-1459   | 0      |
| 1348 | Antiplatelet therapy in elderly patients with acute coronary syndrome: Between scientific evidence and future perspectives. <b>2018</b> , 88, 952 | 0      |
| 1347 | Management des akuten Koronarsyndroms. <b>2018</b> , 12, 371-390  | 3      |
| 1346 | Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. <b>2018</b> , 17, 1041-1052 | 12     |
| 1345 | Medication-based versus target-based lipid management. <b>2018</b> , 10, 789-792  | 0      |
| 1344 | Polyvascular disease and risk: When two is not better than one. <b>2018</b> , 23, 531-533   | 4      |
| 1343 | It must be true □ read it in the tabloids. <b>2018</b> , 48, 251-256  | 1      |
| 1342 | COMMANDER HF - A Trial and an Answer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1372-1374                                       | 59.2 1 |
| 1341 | Landmark Trials in Cardiology in 2017-Celebrating 40 Years of Angioplasty. <b>2018</b> , 27, 167-173  | 3      |
| 1340 | Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities. <b>2018</b> , 13, 1675-1690                | 4      |
| 1339 | Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?. <b>2018</b> , 138, 858-860    | 5      |
| 1338 | Andexanet alfa for the treatment of hemorrhage. <b>2018</b> , 11, 847-855   | 2      |
| 1337 | Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. <b>2018</b> , 17, 138                                | 58     |
| 1336 | 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <b>2018</b> , 34, 1371-1392      | 144    |
| 1335 | Kommentar zu den Leitlinien (2017) der ESC zu peripheren arteriellen Erkrankungen. <b>2018</b> , 12, 241-249                                      | 2      |
| 1334 | NOAKs bei Patienten mit KHK: Wann ist eine Gerinnungsanalytik sinnvoll?. <b>2018</b> , 14, 239-249  |        |
| 1333 | Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. <b>2018</b> , 40, 447-461   |        |
| 1332 | Testing and monitoring direct oral anticoagulants. <b>2018</b> , 132, 2009-2015   | 39     |

1331 Antithrombotische Therapie bei Vorhofflimmern und KHK. **2018**, 18, 24-29

1330 Patients with Peripheral Artery Disease in the COMPASS Trial. **2018**, 56, 772-773 6

1329 Is there an effect of antithrombotics on carotid intraplaque haemorrhage?. **2018**, 39, 3377-3380 2

1328 Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. **2018**, 2, 715-730 24

1327 Prevention of Heart Failure With SGLT-2 Inhibition: Insights From CVD-REAL. **2018**, 71, 2507-2510 7

1326 Novel aspects of antiplatelet therapy in cardiovascular disease. **2018**, 2, 439-449 28

1325 Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. **2018**, 71, 2450-2467 27

1324 Integrating platelet and coagulation activation in fibrin clot formation. **2018**, 2, 450-460 68

1323 Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. **2018**, 17, 53-68 1

1322 Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry". **2018**, 264, 64-69 7

1321 Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence. **2018**, 118, 959-978 23

1320 Pleiotropic effects of the hemostatic system. **2018**, 16, 1464 10

1319 Antithrombotic Therapy and Major Adverse Limb Events in Peripheral Artery Disease: A Step Forward. **2018**, 71, 2316-2318 5

1318 Fibrin Clot Strength in Patients with Diabetes Mellitus Measured by Thrombelastography. **2018**, 2018, 4543065 6

1317 Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. **2018**, 270, 54-59 14

1316 Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban. **2018**, 34, 2053-2061 1

1315 Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. **2018**, 72, 17-26 34

1314 Rivaroxaban: searching the integral vascular protection. **2018**, 11, 719-728 7

|      |  |     |
|------|--|-----|
| 1313 | H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review. <b>2018</b> , 140, 115-123                                  | 8   |
| 1312 | Triple Therapy: When, if Ever?. <b>2018</b> , 20, 61   | 1   |
| 1311 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <b>2018</b> , 15, 480-496   | 134 |
| 1310 | Proteases, Protease-Activated Receptors, and Atherosclerosis. <b>2018</b> , 38, 1252-1254  | 11  |
| 1309 | Association of Blood Pressure Measurements With Peripheral Artery Disease Events. <b>2018</b> , 138, 1805-1814   | 38  |
| 1308 | Direct oral anticoagulants: An update. <b>2018</b> , 151, 198-206  | 3   |
| 1307 | [Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)]. <b>2018</b> , 143, 1060-1064   | 4   |
| 1306 | Critical appraisal of the COMPASS trial. <b>2018</b> , 4, 191-192  | 2   |
| 1305 | Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. <b>2018</b> , 20, 145-166   | 22  |
| 1304 | Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation. <b>2018</b> , 72, 477-485   | 24  |
| 1303 | Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. <b>2018</b> , 5, 1   | 59  |
| 1302 | Prüfung peri- und postinterventionelle Antikoagulation. <b>2018</b> , 155-159  |     |
| 1301 | Tratamiento antitrombótico en síndrome coronario agudo: buscando el equilibrio. <b>2018</b> , 71, 782-786  | 2   |
| 1300 | NOAKs bei arteriellen Rekonstruktionen in der Gefäßmedizin. <b>2018</b> , 23, 76-81  |     |
| 1299 | Perspektiven der Atherothrombose-therapie nach der COMPASS-Studie. <b>2018</b> , 47, 172-175   |     |
| 1298 | Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. <b>2018</b> , 19, 19 | 5   |
| 1297 | [Cardiovascular outcomes for people using anticoagulation strategies : COMPASS]. <b>2018</b> , 59, 636-638   |     |
| 1296 | Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <b>2018</b> , 201, 25-32                         | 6   |

|      |  |      |      |
|------|--|------|------|
| 1295 | Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. <b>2018</b> , 3, 642-649  |      | 111  |
| 1294 | Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis. <b>2018</b> , 75, 1511-1518  |      | 16   |
| 1293 | A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: Applicability and relevance in Indian patients with stable cardiovascular disease. <b>2018</b> , 70, 911-914 |      | 3    |
| 1292 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1529-1539   | 59.2 | 532  |
| 1291 | Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1332-1342  | 59.2 | 181  |
| 1290 | Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. <b>2018</b> , 34, 1426-1436   |      | 6    |
| 1289 | Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism. <b>2018</b> , 16, 501-514  |      | 2    |
| 1288 | Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <b>2018</b> , 391, 2325-2334   |      | 142  |
| 1287 | Direct oral anticoagulants for postoperative myocardial injury. <b>2018</b> , 391, 2297-2298   |      | 4    |
| 1286 | A clinical and proteomics approach to predict the presence of obstructive peripheral arterial disease: From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. <b>2018</b> , 41, 903-909          |      | 9    |
| 1285 | Monocytes as immune targets in arterial hypertension. <b>2019</b> , 176, 1966-1977   |      | 15   |
| 1284 | Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <b>2019</b> , 14, 270-281                        |      | 9    |
| 1283 | Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. <b>2019</b> , 8, 176-185   |      | 13   |
| 1282 | Endoscopic Therapy for Upper GI Bleeding on Antithrombotics - A Safe Option or Do Questions Remain?. <b>2019</b> , 17, 400-401   |      | 0    |
| 1281 | Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. <b>2019</b> , 40, 1466-1471  |      | 17   |
| 1280 | Ascertainment and validation of major bleeding events in a primary care database. <b>2019</b> , 28, 148-155  |      | 10   |
| 1279 | The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease. <b>2019</b> , 24, 103-112   |      | 5    |
| 1278 | 2018 ESC/EACTS Guidelines on myocardial revascularization. <b>2019</b> , 40, 87-165  |      | 2408 |

|      |  |     |
|------|--|-----|
| 1277 | Approaches to Direct Oral Anticoagulant Selection in Practice. <b>2018</b> , 1074248418793137  | 4   |
| 1276 | 2018 ESC/EACTS Guidelines on myocardial revascularization. <b>2019</b> , 55, 4-90  | 251 |
| 1275 | Temporal trends in the management and clinical outcomes of lower extremity arterial thromboembolism within a national Veteran population. <b>2019</b> , 24, 41-49  | 2   |
| 1274 | 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European | 155 |
| 1273 | Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. <b>2019</b> , 12, e007604<br>Am So. <b>2019</b> , 21, 192-193   | 5   |
| 1272 | Modulation of endothelial cell responses and vascular function by dietary fatty acids. <b>2019</b> ,   | 11  |
| 1271 | Higher bleeding rates in patients taking rivaroxaban following an embolic stroke of undetermined source. <b>2019</b> , 49, 310-310   |     |
| 1270 | CHADSVASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. <b>2019</b> , 26, 1987-1997   | 12  |
| 1269 | Atherosclerosis. <b>2019</b> , 5, 56   | 657 |
| 1268 | Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator. <b>2019</b> , 36, 2296-2309  | 1   |
| 1267 | Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice. <b>2019</b> , 9, 11206   | 13  |
| 1266 | Stroke Prevention with Non-Vitamin K Oral Anticoagulants: For Most, but Not for All!. <b>2019</b> , 143, 121-123   | 1   |
| 1265 | Myocardial Infarction-From Atherosclerosis to Thrombosis. <b>2019</b> , 39, e176-e185  | 39  |
| 1264 | Inflammatory Cytokines Associated With Failure of Lower-Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes. <b>2019</b> , 42, 1939-1945   | 13  |
| 1263 | Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?. <b>2019</b> , 24, 100401  | 2   |
| 1262 | The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era. <b>2019</b> , 115, e121-e124   | 3   |
| 1261 | Targeting coagulation in heart failure with preserved ejection fraction and cardiac fibrosis. <b>2019</b> , 40, 3333-3335  | 3   |
| 1260 | Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. <b>2019</b> , 10, 2040620719861475  | 2   |

|      |   |     |
|------|---|-----|
| 1259 | Definitions, adjudication, and reporting of pulmonary embolism-related death in clinical studies: A systematic review. <b>2019</b> , 17, 1590-1607  | 19  |
| 1258 | Peripheral Artery Disease: Past, Present, and Future. <b>2019</b> , 132, 1133-1141  | 49  |
| 1257 | Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <b>2019</b> , 215, 106-113   | 5   |
| 1256 | Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <b>2019</b> , 157, 682-691.e2   | 181 |
| 1255 | In-stent Massive Thrombi Formation During Primary Percutaneous Coronary Intervention in a Patient with Acute Myocardial Infarction Complicated with Essential Thrombocythemia. <b>2019</b> , 58, 1287-1293                  | 7   |
| 1254 | Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA). <b>2019</b> , 124, 1198-1206 | 7   |
| 1253 | Cognitive improvement after carotid artery stenting in patients with symptomatic internal carotid artery near-occlusion. <b>2019</b> , 404, 86-90   | 5   |
| 1252 | Towards Personalized Antithrombotic Treatments: Focus on P2Y Inhibitors and Direct Oral Anticoagulants. <b>2019</b> , 58, 1517-1532   | 4   |
| 1251 | Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. <b>2019</b> , 21, 38   |     |
| 1250 | Pharmacological Therapy of Peripheral Artery Disease in Patients with Diabetes Mellitus: Cardiovascular Risk Factor Management. <b>2019</b> , 20, 24  |     |
| 1249 | Les patients inclus dans COMPASS sont-ils ceux de notre pratique?: Does the study population of the COMPASS trial reflect our daily practice?. <b>2019</b> , 11, S20-S27  |     |
| 1248 | Optimizing the Use of Biomarkers in the ER. <b>2019</b> , 43-71   |     |
| 1247 | Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <b>2019</b> , 73, 3271-3280  | 56  |
| 1246 | Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). <b>2019</b> , 74, 699-711   | 14  |
| 1245 | Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. <b>2019</b> , 73, 3281-3291   | 21  |
| 1244 | Heterogeneity of Risk and Benefit in Subgroups of COMPASS: Relatively Similar But Absolutely Different. <b>2019</b> , 73, 3292-3294   | 0   |
| 1243 | Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <b>2019</b> , 157, 403-412.e5                                       | 62  |
| 1242 | Rivaroxaban May Increase Platelet Activation In Vivo via Thromboxane A2. <b>2019</b> , 125, e9  | 4   |

|      |  |    |
|------|--|----|
| 1241 | Role of rivaroxaban in the prevention of atherosclerotic events. <b>2019</b> , 12, 771-780   | 7  |
| 1240 | A Review of Antithrombotic Treatment in Critical Limb Ischemia After Endovascular Intervention. <b>2019</b> , 8, 193-209   | 6  |
| 1239 | . <b>2019</b> , 161, 73  |    |
| 1238 | Myocardial Injury After Noncardiac Surgery. Could Dabigatran Be a First Step in Its Management?. <b>2019</b> , 72, 803-805   |    |
| 1237 | Rivaroxaban plus low-dose aspirin may help reduce CV events. <b>2019</b> , 25, 4   |    |
| 1236 | Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. <b>2019</b> , 74, 1926-1942   | 19 |
| 1235 | Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. <b>2019</b> , 367, l5476                                     | 34 |
| 1234 | The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <b>2019</b> , 218, 46-56 | 30 |
| 1233 | A look back: the quest for thrombosis in heart failure continues after COMMANDER HF. <b>2019</b> , 115, e140-e142  | 3  |
| 1232 | Practice patterns of dual antiplatelet therapy after lower extremity endovascular interventions. <b>2019</b> , 24, 528-535   | 4  |
| 1231 | Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. <b>2019</b> , 184, 44-49                                  | 6  |
| 1230 | Lipid management beyond the guidelines. <b>2019</b> , 62, 384-389  | 6  |
| 1229 | Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation. <b>2019</b> , 184, 8-15   | 2  |
| 1228 | Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <b>2019</b> , 50, 3347-3354                       | 13 |
| 1227 | Fifty years of research on antithrombotic therapy: Achievements and disappointments. <b>2019</b> , 70, 1-7   | 9  |
| 1226 | Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <b>2019</b> , 140, 1792-1801   | 8  |
| 1225 | Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. <b>2019</b> , 183, 159-162   | 6  |
| 1224 | Essen Risk Score in Prediction of Myocardial Infarction After Transient Ischemic Attack or Ischemic Stroke Without Prior Coronary Artery Disease. <b>2019</b> , 50, 3393-3399  | 11 |



|      |   |    |
|------|---|----|
| 1223 | Differences In Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis. <b>2019</b> , 11, 911-921   | 13 |
| 1222 | European Heart Journal - Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723. <b>2019</b> , 5, 183-184   |    |
| 1221 | Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease. <b>2019</b> , 140, 1460-1462                                  | 2  |
| 1220 | International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study. <b>2019</b> , 10, 1177                      | 0  |
| 1219 | Perspektive nach der COMPASS-Studie für KHK- und AVK-Patienten. <b>2019</b> , 48, 73-77   | 0  |
| 1218 | Antiplatelet, anticoagulant or both? A tool for pharmacists. <b>2019</b> , 152, 291-300   | 2  |
| 1217 | DAPT Cessation and MACE in Elderly Patients: What Is the Optimal Regimen and Duration?. <b>2019</b> , 12, 1626-1627   |    |
| 1216 | Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?. <b>2019</b> , 40, 3779-3781 | 2  |
| 1215 | Is Anticoagulant Necessary in Patients with Coronary Artery Ectasia Presenting with Acute Coronary Syndrome? A Systematic Review of Case Reports. <b>2019</b> , 28, 231-236                               | 5  |
| 1214 | Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios. <b>2019</b> , 21, 115  | 11 |
| 1213 | Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study. <b>2019</b> , 4, 763-775   | 8  |
| 1212 | Paclitaxel-Based Devices for the Treatment of PAD: Balancing Clinical Efficacy with Possible Risk. <b>2019</b> , 21, 57   | 4  |
| 1211 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <b>2019</b> , 40, 3771-3778a   | 19 |
| 1210 | Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <b>2019</b> , 140, 1451-1459  | 22 |
| 1209 | Full Issue PDF. <b>2019</b> , 12, I-CXCVII  |    |
| 1208 | Aspirin in primary prevention: the triumph of clinical judgement over complex equations. <b>2019</b> , 14, 1217-1231  | 3  |
| 1207 | Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies. <b>2019</b> , 289, 118-125   | 4  |
| 1206 | Platelet Acetyl-CoA Carboxylase Phosphorylation: A Risk Stratification Marker That Reveals Platelet-Lipid Interplay in Coronary Artery Disease Patients. <b>2019</b> , 4, 596-610                         | 4  |

|      |  |    |
|------|--|----|
| 1205 | Long Term Evaluation Should Be an Integral Part of the Clinical Implementation of New Vascular Treatments - an ESVS Executive Committee Position Statement. <b>2019</b> , 58, 315-317  | 1  |
| 1204 | Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?: JACC Review Topic of the Week. <b>2019</b> , 74, 1366-1375   | 9  |
| 1203 | Is Bleeding Always Bad?: Bad Boy Bleeding. <b>2019</b> , 74, 1529-1531   | 0  |
| 1202 | Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <b>2019</b> , 74, 1519-1528   | 17 |
| 1201 | Secondary cardiovascular prevention in clinical practice: what do we need today?. <b>2019</b> , 89,  | 1  |
| 1200 | The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants. <b>2019</b> , 56, 1247-1258  | 1  |
| 1199 | Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. <b>2019</b> , 8, e012877  | 24 |
| 1198 | Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <b>2019</b> , 217, 72-83 | 27 |
| 1197 | Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?. <b>2019</b> , 40, 3754-3756   | 0  |
| 1196 | Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review. <b>2019</b> , 21, 5  | 2  |
| 1195 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. <b>2019</b> , 124, 416-425   | 22 |
| 1194 | Antithrombotic Agents. <b>2019</b> , 124, 426-436  | 43 |
| 1193 | Stroke Outcomes in the COMPASS Trial. <b>2019</b> , 139, 1134-1145   | 72 |
| 1192 | The MANAGE trial - Authors' reply. <b>2019</b> , 393, 228  |    |
| 1191 | [Interventional angiology : Endovascular treatment of chronic and acute limb ischemia]. <b>2019</b> , 60, 149-160  |    |
| 1190 | Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. <b>2019</b> , 19, 343-348  | 7  |
| 1189 | Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. <b>2019</b> , 132, e569-e580  | 11 |
| 1188 | Monitoring Emerging Data From the 'COMPASS Trial of an Antithrombotic' Agent. <b>2019</b> , 73, 2769-2772  | 3  |

|      |   |     |
|------|---|-----|
| 1187 | Performance of a clinical/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus. <b>2019</b> , 6, e000955   | 7   |
| 1186 | TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients. <b>2019</b> , 95, 372-377   | 0   |
| 1185 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <b>2019</b> , 5, 200-206  | 17  |
| 1184 | Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. <b>2019</b> , 321, 2414-2427 | 362 |
| 1183 | Role of aspirin in primary prevention of cardiovascular disease. <b>2019</b> , 16, 675-686  | 57  |
| 1182 | A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <b>2019</b> , 40, 3593-3602                     | 38  |
| 1181 | Acute Limb Ischemia in Peripheral Artery Disease. <b>2019</b> , 140, 556-565  | 37  |
| 1180 | Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <b>2019</b> , 140, 529-537  | 50  |
| 1179 | Antiplatelet Therapy and Coronary Artery Bypass Grafting: Analysis of Current Evidence With a Focus on Acute Coronary Syndrome. <b>2019</b> , 35, 1030-1038   | 6   |
| 1178 | Treatment Approaches to Lacunar Stroke. <b>2019</b> , 28, 2055-2078   | 17  |
| 1177 | Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. <b>2019</b> , 213, 81-90                                     | 4   |
| 1176 | Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS. <b>2019</b> , 14, 915-922  | 10  |
| 1175 | Antiagrégant et anticoagulant en association dans la maladie coronaire chronique : rationnel d'une double voie d'inhibition. <b>2019</b> , 11, S11-S19  |     |
| 1174 | Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ?. <b>2019</b> , 11, S28-S39  |     |
| 1173 | Un risque thrombotique persistant malgré les traitements de rffice. <b>2019</b> , 11, S4-S10  |     |
| 1172 | Peut-on personnaliser le traitement antithrombotique ?. <b>2019</b> , 11, S40-S44   |     |
| 1171 | Editorial: Novel and potential markers for prediction of outcome in patients with acute and chronic coronary heart disease. <b>2019</b> , 6, 66   |     |
| 1170 | Preoperative Management of Oral Anticoagulants. <b>2019</b> , 61-67   |     |

|      |   |     |
|------|---|-----|
| 1169 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <b>2019</b> , 40, 2632-2653                 | 169 |
| 1168 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <b>2019</b> , 140, 240-261   | 183 |
| 1167 | Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed. <b>2019</b> , 73, 2359-2360   |     |
| 1166 | Estimated Long-Term Survival With Eplerenone. <b>2019</b> , 73, 2357-2359   | 5   |
| 1165 | Reply: Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed. <b>2019</b> , 73, 2360   |     |
| 1164 | Frontiers in today's chronic coronary syndromes: detecting obstructive disease, role of beta-blockers and of anticoagulants. <b>2019</b> , 40, 1387-1390  |     |
| 1163 | Atrial fibrillation and myocardial infarction - in constant need for new data. <b>2019</b> , 26, 1370-1372  | 2   |
| 1162 | Association Between Unrecognized Myocardial Infarction and Cerebral Infarction on Magnetic Resonance Imaging. <b>2019</b> , 76, 956-961   | 16  |
| 1161 | Ischaemic and bleeding risk assessment after myocardial infarction: combination is the key. <b>2019</b> , 105, 1138-1139  | 1   |
| 1160 | Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. <b>2019</b> , 73, 2243-2250   | 24  |
| 1159 | Antithrombotic dose: Some observations from published clinical trials. <b>2019</b> , 85, 2194-2197  | 1   |
| 1158 | Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction. <b>2019</b> , 105, 1175-1181  | 6   |
| 1157 | [Anti-Thrombotic Therapy of Peripheral Arterial Disease - A Review of Current Evidence, Practice and Outlook]. <b>2019</b> , 144, 683-689   | 1   |
| 1156 | Potential different impact of inhibition of thrombin function and thrombin generation rate for the growth of thrombi formed at site of endothelial injury under blood flow condition. <b>2019</b> , 179, 121-127      | 3   |
| 1155 | Left Atrial Mechanical Function and Incident Ischemic Cerebrovascular Events Independent of AF: Insights From the MESA Study. <b>2019</b> , 12, 2417-2427   | 31  |
| 1154 | Antithrombotic Therapy in Heart Failure-The Clot Thickens. <b>2019</b> , 4, 524-525   |     |
| 1153 | European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage. <b>2019</b> , 4, 294-306  | 38  |
| 1152 | Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. <b>2019</b> , 21, 2107-2114 | 21  |

|      |   |    |
|------|---|----|
| 1151 | Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review. <b>2019</b> , 21, 56  | 4  |
| 1150 | Hacked by the Russians or fake news. <b>2019</b> , 158, e46-e47   |    |
| 1149 | Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. <b>2019</b> , 73, 2049-2058  | 12 |
| 1148 | Thromboembolism in the Absence of Atrial Fibrillation. <b>2019</b> , 124, 303-311   | 12 |
| 1147 | Residual cardiovascular risk among people with diabetes. <b>2019</b> , 21 Suppl 1, 28-38  | 25 |
| 1146 | Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. <b>2019</b> , 40, 3318-3332   | 19 |
| 1145 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. <b>2019</b> , 4, 515-523 | 34 |
| 1144 | Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. <b>2019</b> , 11, 601-604  | 1  |
| 1143 | Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <b>2019</b> , 139, 2170-2185   | 49 |
| 1142 | Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study. <b>2019</b> , 27, 487-497   | 4  |
| 1141 | Kombinierte antithrombotische Therapiestrategien in der Kardiologie. <b>2019</b> , 15, 63-72  |    |
| 1140 | Antithrombotic Therapy After Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next. <b>2019</b> , 53, 325-336  | 1  |
| 1139 | Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial. <b>2018</b> , 24, 4516-4517   | 6  |
| 1138 | Update kardiovaskuläre Risikofaktoren. <b>2019</b> , 15, 43-57  |    |
| 1137 | Predicting stroke in patients without atrial fibrillation. <b>2019</b> , 49, e13103   | 4  |
| 1136 | Atrial fibrillation and stroke: a practical guide. <b>2019</b> , 19, 208-224  | 13 |
| 1135 | Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, But Where Are We Headed?. <b>2019</b> , 8, e012014   | 2  |
| 1134 | Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. <b>2019</b> , 73, 989-999   | 80 |

|      |   |          |
|------|---|----------|
| 1133 | Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51. <b>2019</b> , 8, | 2        |
| 1132 | External applicability of the COMPASS trial: the Western Denmark Heart Registry. <b>2019</b> , 5, 192-199   | 7        |
| 1131 | Aspirin. <b>2019</b> , 921-936  | 2        |
| 1130 | Do the Results of RE-SPECT ESUS Call for a Revision of the Embolic Stroke of Undetermined Source Definition?. <b>2019</b> , 50, 1032-1033   | 12       |
| 1129 | The Role of Platelets in Diabetes Mellitus. <b>2019</b> , 469-503   | 6        |
| 1128 | Novel Antiplatelet Therapies. <b>2019</b> , 991-1015  | 1        |
| 1127 | Antiplatelet Drugs in the Management of Coronary Artery Disease. <b>2019</b> , 1017-1029  |          |
| 1126 | Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. <b>2019</b> , 1067-1077  |          |
| 1125 | Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease. <b>2019</b> , 123, 1893-1899                 | 15       |
| 1124 | Tailoring the Approach to Embolic Stroke of Undetermined Source: A Review. <b>2019</b> , 76, 855-861  | 58       |
| 1123 | Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. <b>2019</b> , 105, 1325-1334  | 17       |
| 1122 | The combination of coronary artery disease and type 2 diabetes: a therapeutic challenge. <b>2019</b> , 21, C37-C39  |          |
| 1121 | Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. <b>2019</b> , 105, 1487-1492  | 1        |
| 1120 | Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. <b>2019</b> , 19, 525-539  | 5        |
| 1119 | High CHADS-VASc score without atrial fibrillation: 'NAO yes, NAO no'. <b>2019</b> , 21, B67-B68   | 1        |
| 1118 | The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <b>2019</b> , 35, e3145   | 4        |
| 1117 | Aspirin suppresses NF $\kappa$ B1 expression and inactivates cAMP signaling pathway to treat atherosclerosis. <b>2019</b> , 45, 343-354   | 4        |
| 1116 | Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1326-1335  | 59.2 431 |

|      |   |    |
|------|---|----|
| 1115 | Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review. <b>2019</b> , 24, 141-152                 | 4  |
| 1114 | Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. <b>2019</b> , 163, 111-118                          | 11 |
| 1113 | Optimizing DAPT Duration in High-Risk Patients After Coronary Stent Implantation: Bleeding Risk Takes It All. <b>2019</b> , 73, 755-757                                     | 3  |
| 1112 | Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome. <b>2019</b> , 73, 775-778   | 3  |
| 1111 | Antithrombotics in stable peripheral artery disease. <b>2019</b> , 24, 132-140  | 8  |
| 1110 | Newest Antithrombotic Agents: Uses, Challenges, and Reversal Strategies for Surgical Procedures. <b>2019</b> , 481-497  |    |
| 1109 | The year in cardiology 2018: heart failure. <b>2019</b> , 40, 651-661   | 19 |
| 1108 | Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <b>2019</b> , 286, 198-207                                   | 13 |
| 1107 | Stable Ischemic Heart Disease. <b>2019</b> , 171, ITC17-ITC32   | 8  |
| 1106 | Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. <b>2019</b> , 171, 181-189                               | 44 |
| 1105 | Lesi3 mioc3rdica tras la cirug3 no cardiaca: 3el dabigatr3 puede ser un primer paso para su tratamiento?. <b>2019</b> , 72, 803-805   |    |
| 1104 | Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke. <b>2019</b> , 93, e695-e707  | 8  |
| 1103 | Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. <b>2019</b> , 15, 395-404   | 2  |
| 1102 | Rivaroxaban Effects Illustrate the Underestimated Importance of Activated Platelets in Thrombin Generation Assessed by Calibrated Automated Thrombography. <b>2019</b> , 8, | 5  |
| 1101 | Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. <b>2019</b> ,                                      | 1  |
| 1100 | How To Assess a Claudication and When To Intervene. <b>2019</b> , 21, 138   | 6  |
| 1099 | Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. <b>2019</b> , 218, 100-109                      | 4  |
| 1098 | Neues beim Schlaganfall unter besonderer Ber3cksichtigung 3terer Patienten. <b>2019</b> , 2, 243-263  |    |

|      |  |    |
|------|--|----|
| 1097 | Dabigatran in patients with myocardial injury after non-cardiac surgery. Report on the MANAGE Trial. <b>2019</b> , 66, 455-458   |    |
| 1096 | Does rivaroxaban have a role in treating patients with PAD?. <b>2019</b> , 32, 16-17   | 1  |
| 1095 | Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. <b>2019</b> , 34, 315-322   | 1  |
| 1094 | Recent evidence for direct oral anticoagulants in chronic kidney disease. <b>2019</b> , 28, 251-261  | 4  |
| 1093 | Risk factor reduction in type 2 diabetes demands a multifactorial approach. <b>2019</b> , 26, 81-91  | 6  |
| 1092 | [Dual Pathway Inhibition in Atherosclerosis - Which Patients Benefit?]. <b>2019</b> , 144, 1384-1389   | 1  |
| 1091 | Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease. <b>2019</b> , 26, 92-105  | 2  |
| 1090 | Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. <b>2019</b> , 8,   | 2  |
| 1089 | Polyvascular Disease: Reappraisal of the Current Clinical Landscape. <b>2019</b> , 12, e007385   | 18 |
| 1088 | PPI nicht so schlecht wie ihr Ruf. <b>2019</b> , 6, 11-12  |    |
| 1087 | COMPASS for Vascular Surgeons: Practical Considerations. <b>2019</b> , 34, 178-184   | 4  |
| 1086 | Successful COMPASS, Disappointing COMMANDER HF, What Have We Learned From These Two Trials?. <b>2019</b> , 74, 306-307   | 3  |
| 1085 | Translational Implications for Targeting Ischemia-Induced Cardiac Inflammation by Ticagrelor: One Fits All or Dose Matters?. <b>2019</b> , 74, 9-12  |    |
| 1084 | Between Scylla and Charybdis: combining anticoagulants with platelet inhibitors and outcome. <b>2019</b> , 40, 3737-3740   | 1  |
| 1083 | Neuro-arrhythmology: a challenging field of action and research: a review from the Task Force of Neuro-arrhythmology of Italian Association of Arrhythmias and Cardiac Pacing. <b>2019</b> , 20, 731-744 | 8  |
| 1082 | Antithrombotic Management After Intracranial Hemorrhage. <b>2019</b> , 21, 88  | 2  |
| 1081 | Antithrombotic Management of Ischemic Stroke. <b>2019</b> , 21, 78   | 6  |
| 1080 | Trends in management and outcome of patients with non-ST elevation acute coronary syndromes and peripheral arterial disease. <b>2019</b> , 59, 70-76   | 8  |



|      |   |     |
|------|---|-----|
| 1079 | Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. <b>2019</b> , 19, 37-47 | 5   |
| 1078 | Anticoagulation in the cardiac patient: A concise review. <b>2019</b> , 102, 3-19   | 5   |
| 1077 | The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <b>2019</b> , 278, 7-13  | 11  |
| 1076 | Histopathologic Characterization of Peripheral Arteries in Subjects With Abundant Risk Factors: Correlating Imaging With Pathology. <b>2019</b> , 12, 1501-1513                                 | 28  |
| 1075 | Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?. <b>2019</b> , 24, 215-224                                  | 4   |
| 1074 | Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention. <b>2019</b> , 27, 299-311   | 5   |
| 1073 | Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism. <b>2019</b> , 108, 787-796                                   | 4   |
| 1072 | Update: Diagnosis and Management of Peripheral Arterial Disease. <b>2019</b> , 15, 87-95.e1   | 5   |
| 1071 | 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <b>2019</b> , 64, 166-179  | 17  |
| 1070 | A farewell to aspirin in primary prevention?. <b>2019</b> , 16, 76-77   | 3   |
| 1069 | The "Fragility" of Mortality Benefit of Coronary Artery Bypass Graft Surgery in Diabetics. <b>2019</b> , 73, 639-642  | 0   |
| 1068 | Platelet biology and functions: new concepts and clinical perspectives. <b>2019</b> , 16, 166-179   | 269 |
| 1067 | Antithrombotic Therapy Following CABG: For the Patient, Not the Bypass Graft. <b>2019</b> , 73, 131-133   | 2   |
| 1066 | The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients. <b>2019</b> , 20, 261-268  |     |
| 1065 | Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. <b>2019</b> , 73, 121-130   | 46  |
| 1064 | Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <b>2019</b> , 12, e007411  | 28  |
| 1063 | Cost-effectiveness analysis: A tool in the hands of the clinician. <b>2019</b> , 26, 855-857  | 0   |
| 1062 | Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects. <b>2019</b> , 18, 5  | 18  |

|      |  |    |
|------|--|----|
| 1061 | Review of the 2017 European Society of Cardiology's Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation and Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with the European Association for Cardio-Thoracic Surgery. <b>2019</b> , 33, 2334-2343 | 5  |
| 1060 | The first 3500 years of aspirin history from its roots - A concise summary. <b>2019</b> , 113, 1-8   | 65 |
| 1059 | Advances in Antithrombotic Therapy. <b>2019</b> , 39, 7-12   | 24 |
| 1058 | Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <b>2019</b> , 123, 153-158  | 7  |
| 1057 | Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. <b>2019</b> , 40, 295-305  | 32 |
| 1056 | Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?. <b>2019</b> , 195, 1-4   | 5  |
| 1055 | The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. <b>2019</b> , 8, 554-561   | 7  |
| 1054 | Hacked by the Russians. <b>2019</b> , 157, 643   | 2  |
| 1053 | Prognostic impact of residual stenosis after percutaneous coronary intervention in patients with ischemic heart failure - A report from the CHART-2 study. <b>2019</b> , 278, 22-27  | 7  |
| 1052 | Challenges to Risk Determination for Patients With Upper Gastrointestinal Bleeding. <b>2019</b> , 17, 1037-1039  | 0  |
| 1051 | Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. <b>2019</b> , 26, 858-868   | 10 |
| 1050 | Unstable Angina and Non-ST Elevation Myocardial Infarction. <b>2019</b> , 233-259  |    |
| 1049 | [Treatment with oral anticoagulants in older patients: Should warfarin still be prescribed?]. <b>2019</b> , 48, 154-164  | 2  |
| 1048 | Endogenous fibrinolysis in STEMI: important before and after primary PCI. <b>2019</b> , 40, 306-308  | 4  |
| 1047 | Limitations of hazard ratios in clinical trials. <b>2019</b> , 40, 1378-1383   | 27 |
| 1046 | Survival of Patients and Treatment-Related Outcome After Intra-Arterial Thrombolysis for Acute Lower Limb Ischemia. <b>2019</b> , 55, 251-259  | 6  |
| 1045 | Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <b>2019</b> , 8, 186-193  | 9  |
| 1044 | Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. <b>2020</b> , 75, 10-19   | 1  |

|      |  |    |
|------|--|----|
| 1043 | The safety of lasers for BPH surgery in men taking clopidogrel: one cannot judge a book by its cover. <b>2020</b> , 38, 1081-1082  | 2  |
| 1042 | Myocardial injury after non-cardiac surgery: diagnosis and management. <b>2020</b> , 41, 3083-3091   | 55 |
| 1041 | Editorial commentary: Evolving paradigms in antithrombotic therapy for patients with coronary artery disease undergoing percutaneous coronary intervention. <b>2020</b> , 30, 203-204  |    |
| 1040 | Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. <b>2020</b> , 30, 198-202  | 3  |
| 1039 | Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. <b>2020</b> , 9, 788-801   | 1  |
| 1038 | Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. <b>2020</b> , 71, 45-49  | 4  |
| 1037 | Relationship of Anticoagulant Therapies on Coronary Plaque Progression: A Longitudinal CTA Analysis. <b>2020</b> , 13, 169-170   | 4  |
| 1036 | Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. <b>2020</b> , 77, 43-48  | 25 |
| 1035 | Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis. <b>2020</b> , 71, 27-37   | 8  |
| 1034 | Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. <b>2020</b> , 293, 94-100  | 37 |
| 1033 | Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <b>2020</b> , 27, 296-307   | 17 |
| 1032 | MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF NanoCoated Coronary Stent (NCS) Implantation. <b>2020</b> , 21, 785-789  | 6  |
| 1031 | Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. <b>2020</b> , 6, 57-68   | 8  |
| 1030 | Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <b>2020</b> , 6, 86-93 | 15 |
| 1029 | The myth of 'stable' coronary artery disease. <b>2020</b> , 17, 9-21   | 39 |
| 1028 | The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. <b>2020</b> , 6, 97-103   | 4  |
| 1027 | A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. <b>2020</b> , 25, 207-216   | 9  |
| 1026 | Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. <b>2020</b> , 6, 159-166   | 13 |

|      |   |          |
|------|---|----------|
| 1025 | EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. <b>2019</b> ,  | 59       |
| 1024 | 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <b>2020</b> , 41, 407-477   | 1835     |
| 1023 | 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <b>2020</b> , 41, 255-323  | 1360     |
| 1022 | Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <b>2020</b> , 41, 347-356  | 20       |
| 1021 | Prognostic risk factors for recurrent acute lower limb ischemia in patients treated with intra-arterial thrombolysis. <b>2020</b> , 71, 1268-1275   | 2        |
| 1020 | A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 120-129   | 59.2 185 |
| 1019 | Real-World Predictors of Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients with Chronic Coronary Artery Disease and/or Peripheral Arterial Disease. <b>2020</b> , 37, 240-252  | 4        |
| 1018 | Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <b>2020</b> , 43, 24-32   | 6        |
| 1017 | Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <b>2020</b> , 76, 470-485   | 18       |
| 1016 | Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. <b>2020</b> , 160, 108008  | 10       |
| 1015 | Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention. <b>2020</b> , 5, 209-215  | 13       |
| 1014 | Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. <b>2020</b> , 49, 192-198 | 2        |
| 1013 | Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. <b>2020</b> , 59, 173-218   | 122      |
| 1012 | Role of direct oral anticoagulants in patients with kidney disease. <b>2020</b> , 97, 664-675   | 14       |
| 1011 | The therapeutic age paradox coming to an end. <b>2020</b> , 41, 2259-2261   | 2        |
| 1010 | How to reduce risk in secondary prevention: First of all address the basics!. <b>2020</b> , 27, 294-295   |          |
| 1009 | Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <b>2020</b> , 96, 1369-1378  | 3        |
| 1008 | Reply. <b>2020</b> , 158, 285-286   |          |

|      |  |    |
|------|--|----|
| 1007 | Carotid Plaque With High-Risk Features in Embolic Stroke of Undetermined Source: Systematic Review and Meta-Analysis. <b>2020</b> , 51, 311-314                                | 30 |
| 1006 | Screening for atrial fibrillation: a call for evidence. <b>2020</b> , 41, 1075-1085  | 60 |
| 1005 | A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <b>2020</b> , 36, 1298-1307                | 5  |
| 1004 | Finally, the big picture of morbidity and mortality in peripheral arterial disease?. <b>2020</b> , 293, 92-93  | 2  |
| 1003 | Safety of Proton Pump Inhibitors Questioned Based on a Large Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <b>2020</b> , 158, 1172-1173                       | 4  |
| 1002 | Atrial fibrillation and stroke: how much atrial fibrillation is enough to cause a stroke?. <b>2020</b> , 33, 17-23   | 4  |
| 1001 | Apold1 deficiency associates with increased arterial thrombosis in vivo. <b>2020</b> , 50, e13191  | 0  |
| 1000 | Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. <b>2020</b> , 116, 1918-1924         | 14 |
| 999  | Management of peripheral arterial disease in the modern era: an internist "Cup of Tea". <b>2020</b> , 15, 195-197  | 1  |
| 998  | Multiple Faces of Cerebral Small Vessel Diseases. <b>2020</b> , 51, 9-11   | 2  |
| 997  | Is there a link between venous and arterial thrombosis? A reappraisal. <b>2020</b> , 15, 33-36   | 6  |
| 996  | Long-term mortality after massive, submassive, and low-risk pulmonary embolism. <b>2020</b> , 25, 141-149  | 12 |
| 995  | Review of the top 5 cardiology studies of 2017-18. <b>2020</b> , 153, 32-36  | 2  |
| 994  | Myocardial Injury After Noncardiac Surgery: Preoperative, Intraoperative, and Postoperative Aspects, Implications, and Directions. <b>2020</b> , 131, 173-186                  | 24 |
| 993  | Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials. <b>2020</b> , 31, 260-265 | 1  |
| 992  | Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1. <b>2020</b> , 126, 486-500                          | 48 |
| 991  | Hematopoietic Stem Cell Transplantation and Vasculopathy Associated With STAT3-Dominant-Negative Hyper-IgE Syndrome. <b>2020</b> , 8, 575                                      | 3  |
| 990  | Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. <b>2020</b> , 22, 75  | 8  |

|     |   |    |
|-----|---|----|
| 989 | Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. <b>2020</b> , 42, 2084-2097  | 3  |
| 988 | Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. <b>2020</b> , 18, 881-889  | 1  |
| 987 | Secondary prevention after CABG: do new agents change the paradigm?. <b>2020</b> , 35, 664-672  | 1  |
| 986 | Adverse events beyond 1 year after percutaneous coronary intervention. <b>2020</b> , 35, 687-696  | 2  |
| 985 | Evolving Concepts in Post-PCI Antiplatelets Therapy. <b>2020</b> , 1, 186-194   |    |
| 984 | Nanoparticle-based "Two-pronged" approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux. <b>2020</b> , 260, 120333   | 12 |
| 983 | Extended antithrombotic therapy in secondary prevention: "There is no such thing as a free lunch". <b>2020</b> , 39, 503-504  |    |
| 982 | Antiplatelet Therapy for Transient Ischemic Attack and Minor Stroke. <b>2020</b> , 51, 3472-3474  | 2  |
| 981 | [In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke or cardiovascular death compared to aspirin alone while being safe?]. <b>2020</b> , 41, 571-572 |    |
| 980 | Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. <b>2020</b> , 13, e009584   | 5  |
| 979 | The High Bleeding Risk Patient with Coronary Artery Disease. <b>2020</b> , 38, 481-490  |    |
| 978 | Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. <b>2020</b> , 19, 170  | 7  |
| 977 | Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. <b>2021</b> , 6, 21-29  | 12 |
| 976 | Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis. <b>2020</b> ,  |    |
| 975 | Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <b>2020</b> , 22, 74   | 5  |
| 974 | Predictors of atrial fibrillation detection and features of recurrent strokes in patients after cryptogenic stroke. <b>2020</b> , 29, 104934  | 0  |
| 973 | Comentarios a la gu  ESC 2019 sobre s ndromes coronarios cr nicos. <b>2020</b> , 73, 439-444  | 4  |
| 972 | Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. <b>2020</b> , 76, 435-450   | 5  |

|     |   |    |
|-----|---|----|
| 971 | A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <b>2020</b> , 131, 40-48  | 2  |
| 970 | Do Direct Oral Anticoagulants Have Cardiovascular Benefits in CKD? We Need More Evidence. <b>2020</b> , 76, 306-307   |    |
| 969 | Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. <b>2020</b> , 142, 546-555   | 5  |
| 968 | Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review. <b>2020</b> , 9, e015361   | 2  |
| 967 | Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability. <b>2020</b> , 14, 619-630  | 14 |
| 966 | [Direct oral anticoagulants: In which indications? Which one to prescribe? For or against their use in frail patients and in atypical cases? Which monitoring and management haemorrhage complications?]. <b>2020</b> , 41, 598-606 | 0  |
| 965 | Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth. <b>2020</b> , 127, 106661   | 4  |
| 964 | Platelets and coagulation factors: Established and novel roles in atherosclerosis and atherothrombosis. <b>2020</b> , 307, 78-79  | 5  |
| 963 | Novel Oral Anticoagulants Following Percutaneous Coronary Intervention. <b>2020</b> , 13, e008465   | 3  |
| 962 | Postprocedural Antithrombotic Therapy Following Left Atrial Appendage Occlusion: No Longer Adrift in Uncertainty?. <b>2020</b> , 13, e009534  | 2  |
| 961 | Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. <b>2020</b> , 105, 2327-2334   | 15 |
| 960 | Who Needs Gastroprotection in 2020?. <b>2020</b> , 18, 1-17   | 4  |
| 959 | Chronic ischaemic heart disease and rivaroxaban: which patients derive the greatest benefit?. <b>2020</b> , 22, L24-L27   | 0  |
| 958 | CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-The Pros and Cons for Cardioprotection. <b>2020</b> , 21,  | 11 |
| 957 | Direct oral anticoagulants: evidence and unresolved issues. <b>2020</b> , 396, 1767-1776  | 32 |
| 956 | Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. <b>2020</b> , 142, 2172-2188  | 12 |
| 955 | In ACS treated with drug-eluting stents and 3 mo of DAPT, ticagrelor monotherapy reduced clinical events at 1 y vs. DAPT. <b>2020</b> , 173, JC43   |    |
| 954 | Preoperative N-Terminal Pro-B-Type Natriuretic Peptide and Cardiovascular Events After Noncardiac Surgery: A Cohort Study. <b>2020</b> , 172, 96-104  | 43 |

|     |  |    |
|-----|--|----|
| 953 | Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. <b>2020</b> , 315, 10-17   | 5  |
| 952 | Management of carotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a critical review. <b>2020</b> , 22, M35-M42   | 15 |
| 951 | Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. <b>2020</b> , 22, M26-M34   | 1  |
| 950 | Does aspirin prevent venous thromboembolism?. <b>2020</b> , 2020, 634-641  | 3  |
| 949 | Combining antiplatelet and anticoagulant therapy in cardiovascular disease. <b>2020</b> , 2020, 642-648  | 8  |
| 948 | Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time?. <b>2020</b> , 9, e019395   | 5  |
| 947 | VOYAGER PAD contributes to medical therapy for peripheral artery disease. <b>2020</b> , 72, 1843-1844  |    |
| 946 | Antithrombotische Therapie des chronischen Koronarsyndroms. <b>2020</b> , 49, 97-101   |    |
| 945 | Long term efficacy and safety of rivaroxaban plus cilostazol in the treatment of critical ischemia of the lower limbs in a frail, elderly patient with non valvular atrial fibrillation. <b>2020</b> , 6, 17   |    |
| 944 | Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review. <b>2020</b> , 18, 577-585   | 0  |
| 943 | The COMPASS trial: practical considerations for application after coronary artery bypass surgery. <b>2020</b> , 35, 583-588  | 1  |
| 942 | Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. <b>2020</b> , 16, 597-611  |    |
| 941 | Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. <b>2020</b> , 1  | 4  |
| 940 | Vascular thiol isomerases in thrombosis: The yin and yang. <b>2020</b> , 18, 2790-2800   | 12 |
| 939 | Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials. <b>2020</b> , 2020, 3057168  | 6  |
| 938 | Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. <b>2020</b> , 222, 166-173 | 5  |
| 937 | A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. <b>2020</b> , 309, 16-26   | 31 |
| 936 | Aspirin: Bitter pill or miracle drug?. <b>2020</b> , 85, 1-4   | 5  |



|     |   |    |
|-----|---|----|
| 935 | Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist's View. <b>2020</b> , 36, 264-273  | 0  |
| 934 | New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. <b>2020</b> , 77, 1308-1317  | 11 |
| 933 | Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges-A 70-Year Journey. <b>2020</b> , 120, 1352-1356   | 3  |
| 932 | Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice. <b>2020</b> , 19, 1513-1520        | 2  |
| 931 | Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis. <b>2020</b> , 31, 354-363  | 6  |
| 930 | Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. <b>2020</b> , 69, 158-166  | 0  |
| 929 | Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. <b>2020</b> , 35, 517-523   | 2  |
| 928 | Identification of common and divergent gene expression signatures in patients with venous and arterial thrombosis using data from public repositories. <b>2020</b> , 15, e0235501   | 1  |
| 927 | Rare pulmonary embolism caused by the combination of bilateral popliteal venous aneurysms and antiphospholipid syndrome. <b>2020</b> , 13,  | 1  |
| 926 | Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy. <b>2021</b> , 23, 657-660                                   |    |
| 925 | Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. <b>2020</b> , 76, 2252-2266                                   | 18 |
| 924 | Associations between the size and location of myocardial infarction and cerebral infarction. <b>2020</b> , 419, 117182  | 2  |
| 923 | Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients. <b>2020</b> , 196, 523-525 |    |
| 922 | The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <b>2020</b> , 36, 1847-1948              | 82 |
| 921 | Personalization of Aspirin Therapy Ex Vivo in Patients with Atherosclerosis Using Light Transmission Aggregometry. <b>2020</b> , 10,  | 3  |
| 920 | Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. <b>2020</b> , 9,                         | 8  |
| 919 | Targeting Inflammation to Reduce Residual Cardiovascular Risk. <b>2020</b> , 22, 66   | 11 |
| 918 | Letter by Alfaddagh Regarding Article, "Healed Plaques in Patients With Stable Angina Pectoris". <b>2020</b> , 40, e256-e257  |    |

|     |  |     |
|-----|--|-----|
| 917 | Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted?. <b>2020</b> , 142, 1579-1590   | 12  |
| 916 | Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <b>2020</b> , 51, 2901-2909   | 5   |
| 915 | Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <b>2021</b> , 23, 648-656   | 5   |
| 914 | Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. <b>2021</b> , 7, 352-359  | 5   |
| 913 | Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen. <b>2020</b> , 49, 57-61   |     |
| 912 | Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. <b>2020</b> , 18, 733-741   | 3   |
| 911 | A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants. <b>2020</b> , 9,  | 5   |
| 910 | Diabetes, pre-diabetes and cardiovascular diseases in light of the 2019 ESC Guidelines. <b>2020</b> , 36, 148-155  |     |
| 909 | Editor's presentation: Towards a personalised approach in exercise-based cardiovascular rehabilitation: An European Association of Preventive Cardiology (EAPC) call for action. <b>2020</b> , 27, 1347-1349                             | 1   |
| 908 | Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1838-1847  | 396 |
| 907 | Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. <b>2021</b> , 117, 2030-2044  | 4   |
| 906 | Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants. <b>2020</b> , 9,  | 7   |
| 905 | Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <b>2020</b> , 3, e2015943 | 2   |
| 904 | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?. <b>2020</b> , 16, 607-613  | 2   |
| 903 | Kommentar zu den Leitlinien (2019) der ESC zum chronischen Koronarsyndrom. <b>2020</b> , 14, 482-491   | 1   |
| 902 | The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. <b>2020</b> , 9, 489-498                       | 1   |
| 901 | Projecting effectiveness after ending a randomized controlled trial: a two-state Markov microsimulation model. <b>2020</b> , 1-8   |     |
| 900 | Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients. <b>2020</b> , 9,  |     |

|     |   |    |
|-----|---|----|
| 899 | Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. <b>2020</b> , 80, 1465-1475   | 2  |
| 898 | Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition. <b>2020</b> , 40, 2678-2685   | 1  |
| 897 | Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. <b>2020</b> , 41, 3998-4007   | 26 |
| 896 | Peripheral Arterial Disease Located in the Feet of Patients With Diabetes and Foot Ulceration Demands a New Approach to the Assessment of Ischemia. <b>2020</b> , 1534734620947979  | 2  |
| 895 | Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. <b>2020</b> , 76, 173-180   | 21 |
| 894 | Long-term Antithrombotic Therapy for Large and Small Artery Occlusive Disease. <b>2020</b> , 384-411  |    |
| 893 | Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery. <b>2020</b> , 10, 19360  | 0  |
| 892 | Stroke Prevention in Atrial Fibrillation: Looking Forward. <b>2020</b> , 142, 2371-2388   | 10 |
| 891 | Management of Acute Coronary Syndromes Beyond the First Year: A Canadian Clinical Practice Survey. <b>2020</b> , 2, 619-624   |    |
| 890 | The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <b>2021</b> , 7, 453-459    | 1  |
| 889 | Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic Review. <b>2021</b> , 55, 995-1009 | 1  |
| 888 | Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome. <b>2020</b> , 39, 493-501  | 3  |
| 887 | Long-Term Outcomes After Revascularization for Stable Ischemic Heart Disease: An Individual Patient-Level Pooled Analysis of 19 Randomized Coronary Stent Trials. <b>2020</b> , 13, e008565                               | 6  |
| 886 | Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). <b>2020</b> , 73, 404.e1-404.e59                                     | 2  |
| 885 | Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?. <b>2020</b> , 75, 269-275  | 3  |
| 884 | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients. <b>2020</b> , 16, 99-107  |    |
| 883 | Meta-Analysis of Antithrombotic Strategies in Patients With Heart Failure With Reduced Ejection Fraction and Sinus Rhythm. <b>2020</b> , 127, 92-98   | 3  |
| 882 | VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. <b>2020</b> , 190, 112-121  | 4  |

|     |  |     |
|-----|--|-----|
| 881 | Paciente con alto riesgo cardiovascular y fibrilaci3n auricular: papel del rivaroxab3n. <b>2020</b> , 20, 30-38  |     |
| 880 | Monotherapy with a P2Y inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. <b>2020</b> , 395, 1487-1495                           | 46  |
| 879 | Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1". <b>2020</b> , 126, e116-e117 | 1   |
| 878 | Meta-analysis of cardiovascular superiority trials published in the to elucidate the concept of superiority margin. <b>2021</b> , 97, 227-233  |     |
| 877 | Fibrilaci3n auricular y cardiopat3a isqu3mica: m3n all3 de la prevenci3n del ictus. <b>2020</b> , 20, 11-20  |     |
| 876 | The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead. <b>2020</b> , 25, 391-398   | 2   |
| 875 | Altered coagulation profile in peripheral artery disease patients. <b>2020</b> , 28, 368-377   | 7   |
| 874 | Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1". <b>2020</b> , 126, e114-e115               | 1   |
| 873 | The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. <b>2020</b> , 26, 782-785   | 3   |
| 872 | Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. <b>2020</b> , 213, 107592  | 20  |
| 871 | The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <b>2020</b> , 7, 88  | 29  |
| 870 | Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. <b>2020</b> , 19, 63          | 17  |
| 869 | Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma. <b>2020</b> , 15, 1169-1181   | 3   |
| 868 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <b>2020</b> , 120, 1004-1024  | 147 |
| 867 | Network Pharmacology-Based Approach to Investigate the Mechanisms of Mahai Capsules in the Treatment of Cardiovascular Diseases. <b>2020</b> , 2020, 9180982   | 3   |
| 866 | Effectiveness of Adding Antiplatelets to Oral Anticoagulants in Patients with Acute Ischemic Stroke with Atrial Fibrillation and Concomitant Large Artery Steno-Occlusion. <b>2020</b> , 11, 1322-1331           | 3   |
| 865 | The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. <b>2020</b> , 142, 40-48  | 29  |
| 864 | Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. <b>2020</b> , 130, 106679   | 3   |

|     |   |     |
|-----|---|-----|
| 863 | Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). <b>2020</b> , 60, 29 | 3   |
| 862 | MicroRNA-126 is a regulator of platelet-supported thrombin generation. <b>2020</b> , 31, 746-755  | 6   |
| 861 | Transcatheter Left Atrial Appendage Occlusion in the DOAC Era. <b>2020</b> , 75, 3136-3139  | 4   |
| 860 | Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <b>2020</b> , 75, 3140-3147  | 23  |
| 859 | Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. <b>2020</b> , 1   | 1   |
| 858 | Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results. <b>2020</b> , 22, E137-E141                               | 1   |
| 857 | Diabetes and coronary artery disease: not just a risk factor. <b>2020</b> , 106, 1357-1364  | 4   |
| 856 | Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. <b>2020</b> , 9, e017559  | 101 |
| 855 | Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. <b>2020</b> , 37, 3348-3369  | 2   |
| 854 | COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. <b>2021</b> , 7, 513-520                                 | 2   |
| 853 | Optimal antiplatelet and anticoagulation strategies in acute coronary syndromes. <b>2020</b> , 45, 528-536  | 1   |
| 852 | Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease: A Focus on Diabetes Mellitus as a High-Risk Patient Group. <b>2020</b> , 141, 1855-1858                           |     |
| 851 | Targeting cardiovascular inflammation: next steps in clinical translation. <b>2021</b> , 42, 113-131  | 63  |
| 850 | Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <b>2020</b> , 141, 1141-1151   | 21  |
| 849 | [Second look: practical diagnostic and therapeutic checks in neurorehabilitation]. <b>2020</b> , 91, 324-336  | 0   |
| 848 | JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. <b>2020</b> , 84, 831-865   | 77  |
| 847 | Antiplatelet therapies in diabetes. <b>2020</b> , 37, 726-734   |     |
| 846 | Intensified P2Y12 inhibition for high-on treatment platelet reactivity. <b>2020</b> , 50, 619-627   | 1   |

|     |   |      |     |
|-----|---|------|-----|
| 845 | Acute Coronary Syndromes and the Nontarget Lesion. <b>2020</b> , 75, 1107-1110  |      | 1   |
| 844 | Abnormal ankle-brachial index (ABI) predicts primary and secondary cardiovascular risk and cancer mortality. <b>2020</b> , 77, 79-85  |      | 5   |
| 843 | Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. <b>2020</b> , 5, 598-607   |      | 29  |
| 842 | Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. <b>2020</b> , 4, 413-421   |      | 4   |
| 841 | Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1994-2004   | 59.2 | 248 |
| 840 | Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <b>2020</b> , 141, 1841-1854   |      | 53  |
| 839 | Antithrombotic regimen for ischemic stroke patients with concomitant atrial fibrillation and extracranial/intracranial artery stenosis: what is the best way?. <b>2020</b> , 41, 2621-2624  |      |     |
| 838 | Prevencci3n secundaria antitromb3tica intensiva tard3a luego de un infarto del miocardio ¿Cu3ndo, en qu3dies y c3mo?. <b>2020</b> , 27, 1-3   |      |     |
| 837 | Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. <b>2020</b> , 16, 69-75                                    |      | 1   |
| 836 | Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. <b>2020</b> , 9, 2048004020907002   |      | 1   |
| 835 | Therapeutic strategies for thrombosis: new targets and approaches. <b>2020</b> , 19, 333-352  |      | 82  |
| 834 | Comments on the 2019 ESC guidelines on chronic coronary syndromes. <b>2020</b> , 73, 439-444  |      | 0   |
| 833 | Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. <b>2020</b> , 227, 100-106                      |      | 10  |
| 832 | Regression of Atherosclerosis in ApoE-/- Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotoxic" Anti-Thrombin Without Prolonged Anticoagulation. <b>2020</b> , 9, e014811         |      | 3   |
| 831 | Bleeding associated with low-dose aspirin: Comparison of data from the COMPASS randomized controlled trial and routine clinical practice. <b>2020</b> , 318, 21-24  |      | 3   |
| 830 | Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. <b>2020</b> , 160, 105060 |      | 11  |
| 829 | Late intensive antithrombotic secondary prevention after myocardial infarction. When, in whom and how?. <b>2020</b> , 27, 4-6   |      |     |
| 828 | Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma. <b>2020</b> , 116, e93-e95  |      | 2   |

|     |  |    |
|-----|--|----|
| 827 | Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. <b>2020</b> , 7, 2032-2041  | 33 |
| 826 | Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis. <b>2020</b> , 40, 2018-2032   | 17 |
| 825 | Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis. <b>2020</b> , 95, e480-e487  | 1  |
| 824 | DARE to Prescribe: Strategy to Guide Direct Oral Anticoagulant Therapy. <b>2020</b> , 16, 509-513  | 2  |
| 823 | SOP Pharmakotherapie des chronischen Koronarsyndroms. <b>2020</b> , 16, 101-103  |    |
| 822 | Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. <b>2020</b> , 120, 1147-1158   | 13 |
| 821 | Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis. <b>2020</b> , 95, e499-e507   | 4  |
| 820 | Secondary cardiovascular prevention in patients with previous myocardial infarction: an individualized approach difficult to be tailored. <b>2020</b> , 21, 610-612  |    |
| 819 | Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. <b>2020</b> , 86, 1150-1164  | 22 |
| 818 | P2Y inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. <b>2020</b> , 106, 575-583  | 8  |
| 817 | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease. <b>2020</b> , 15, 873-880   |    |
| 816 | What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?. <b>2020</b> , 189, 216-227   | 9  |
| 815 | Ischemic Heart Disease: An Update. <b>2020</b> , 50, 195-207   | 11 |
| 814 | Proposed antithrombotic strategy for acute ischemic stroke with large-artery atherosclerosis: focus on patients with high-risk transient ischemic attack and mild-to-moderate stroke. <b>2020</b> , 8, 16  | 4  |
| 813 | Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. <b>2020</b> , 50, 421-429  | 0  |
| 812 | Compared with matched controls, patients with postoperative atrial fibrillation (POAF) have increased long-term AF after CABG, and POAF is further associated with increased ischemic stroke, heart failure and mortality even after adjustment for AF. <b>2020</b> , 109, 1232-1242 | 16 |
| 811 | Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. <b>2020</b> , 87, 677   | 41 |
| 810 | Factor Xa Inhibition, A New Strategy for Prevention of Adverse Cardiac Remodeling in Early Stages?. <b>2020</b> , 5, 84-87   | 1  |

|     |  |    |
|-----|--|----|
| 809 | Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload. <b>2020</b> , 5, 69-83  | 5  |
| 808 | Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <b>2020</b> , 311, 7-14   | 4  |
| 807 | Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <b>2020</b> , 17, 360-377  | 41 |
| 806 | Treatment of thrombosis. <b>2020</b> , 105-144   |    |
| 805 | Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <b>2020</b> , 17, 242-257  | 41 |
| 804 | A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause. <b>2020</b> , 187, 32-38   | 3  |
| 803 | The relationship of a Prothrombin G20210A mutation or a factor V Leiden mutation and on-aspirin platelet (re-)activity. <b>2020</b> , 19, 127-130  |    |
| 802 | Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. <b>2020</b> , 22, 13   | 1  |
| 801 | Embolc Stroke of Undetermined Source: JACC Review Topic of the Week. <b>2020</b> , 75, 333-340   | 68 |
| 800 | Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis. <b>2020</b> , 23, 513-520   | 3  |
| 799 | Ticagrelor versus clopidogrel in patients undergoing implantation of paclitaxel-eluting stent in the femoropopliteal district: A randomized pilot study using frequency-domain optical coherence tomography. <b>2020</b> , 304, 192-197                  | 3  |
| 798 | The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes - A call to action. <b>2020</b> , 304, 5-7  | 0  |
| 797 | Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. <b>2020</b> , 11, 683  | 49 |
| 796 | Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <b>2020</b> , 22, 1298-1314 | 23 |
| 795 | Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <b>2020</b> , 2, 402-415   | 0  |
| 794 | Chronisches und akutes Koronarsyndrom. <b>2020</b> , 20, 30-35   |    |
| 793 | Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease. <b>2020</b> , 105, e365-e369  | 7  |
| 792 | Colchicine for Secondary Cardiovascular Prevention: A Systematic Review. <b>2020</b> , 40, 575-583   | 3  |



|     |  |    |
|-----|--|----|
| 791 | [Past and future of the ESUS concept]. <b>2020</b> , 91, 511-517   | 1  |
| 790 | Thrombozytenaggregationshemmung (TAH) und orale Antikoagulation (OAK). <b>2020</b> , 25, 150-159   | 1  |
| 789 | Edoxaban affects TRAP-dependent platelet aggregation. <b>2020</b> , 49, 578-583  | 1  |
| 788 | Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. <b>2020</b> , 75, 1804-1818   | 63 |
| 787 | Novel antithrombotic regimen in patients with ischemic heart disease and peripheral arterial disease: can we identify those who derive the highest benefit?. <b>2020</b> , 23, 670-672   |    |
| 786 | Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. <b>2020</b> , 13, 777-784   | 6  |
| 785 | Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. <b>2020</b> , 76, 311-320  | 10 |
| 784 | Prime Time for Lower Extremity Artery Disease. <b>2019</b> ,   |    |
| 783 | Comprehensive plaque assessment with serial coronary CT angiography: translation to bedside. <b>2020</b> , 36, 2335-2346   | 5  |
| 782 | Selexipag Use in Clinical Practice: Mind the Gap. <b>2020</b> , 157, 761-763   |    |
| 781 | The Voyager PAD Trial - New Path for Post-revascularisation PAD Patients. <b>2020</b> , 59, 699-700  | 4  |
| 780 | The Role of Clopidogrel in 2020: A Reappraisal. <b>2020</b> , 2020, 8703627  | 24 |
| 779 | Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <b>2020</b> , 51, 1797-1804  | 18 |
| 778 | Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. <b>2020</b> , 27, 1354-1365   | 6  |
| 777 | Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemic. <b>2020</b> , 27, 1351-1353 | 4  |
| 776 | Letter by Borst Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1". <b>2020</b> , 126, e53   |    |
| 775 | Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. <b>2020</b> , 50, 913-920  | 5  |
| 774 | Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source. <b>2021</b> , 42, 1789-1796  | 16 |

|     |   |    |
|-----|---|----|
| 773 | Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <b>2021</b> , 117, 576-584   | 10 |
| 772 | Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. <b>2021</b> , 106, 1616-1623   | 1  |
| 771 | Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <b>2021</b> , 117, 942-949   | 7  |
| 770 | Long-term dual antithrombotic therapy (DAT): is it efficient and safe in women?. <b>2021</b> , 117, 653-654   |    |
| 769 | Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. <b>2021</b> , 17, 175-182   | 1  |
| 768 | The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era. <b>2021</b> , 97, 1221-1229   |    |
| 767 | Peripheral artery disease in outpatients with a recent history of acute coronary syndrome or at high atherothrombotic risk. <b>2021</b> , 29, 92-99   | 2  |
| 766 | Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. <b>2018</b> ,   | 2  |
| 765 | Pharmacology before, during and after percutaneous coronary intervention. <b>2020</b> ,   | 1  |
| 764 | Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis. <b>2021</b> , 83, 14-20  | 0  |
| 763 | Antithrombotic therapy for patients with chronic coronary syndromes. <b>2021</b> , 107, 925-933   | 6  |
| 762 | LDL Cholesterol and Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation. <b>2021</b> , 134, 507-513  | 4  |
| 761 | Predicting 10-year risk of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. <b>2021</b> , 325, 140-148 | 3  |
| 760 | A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies. <b>2021</b> , 218, 107676   | 5  |
| 759 | COMPASS vs PEGASUS approach in a comparative budget impact analysis. <b>2021</b> , 83, 102-104  | 0  |
| 758 | How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018. <b>2021</b> , 29, 135-141                            | 0  |
| 757 | Left Atrial Appendage Closure Review: Addressing Unmet Needs of AF Mediated Stroke Prevention with Evolving Science. <b>2021</b> , 5, 3-10  |    |
| 756 | What is new in the 2020 ESC NSTEMI-ACS guidelines. <b>2021</b> , 51, e13422   | 0  |

|     |   |    |
|-----|---|----|
| 755 | Colchicin Eine neue Option für das chronische Koronarsyndrom?. <b>2021</b> , 15, 9-10   |    |
| 754 | New anticoagulants: Moving beyond the direct oral anticoagulants. <b>2021</b> , 19, 20-29   | 15 |
| 753 | [ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation : What is new?]. <b>2021</b> , 46, 3-13   | 2  |
| 752 | Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. <b>2021</b> , 141, 38-48   | 4  |
| 751 | Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus. <b>2021</b> , 142, 14-24  | 1  |
| 750 | Effect of Yugengtongyu Granules in Patients with Stable Coronary Artery Disease on Reducing Adverse Cardiovascular Events: A Double-Blind Controlled Trial. <b>2021</b> , 27, 142-149   | 1  |
| 749 | Dual Antithrombotic Therapy Targeting Residual Risk for Atherosclerotic Cardiovascular Disease: Does Body Mass Index Matter?. <b>2021</b> , 77, 526-528   | 1  |
| 748 | Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <b>2021</b> , 77, 511-525   | 3  |
| 747 | 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. <b>2021</b> , 77, 629-658 | 45 |
| 746 | Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice. <b>2021</b> , 77, 709-716   | 5  |
| 745 | Current Status of Chemoprevention in Barrett's Esophagus. <b>2021</b> , 31, 117-130   | 3  |
| 744 | The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <b>2021</b> , 121, 422-432  | 47 |
| 743 | Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. <b>2021</b> , 44, 58-65   | 1  |
| 742 | Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment. <b>2021</b> , 51, e13471  | 2  |
| 741 | Small Vessel Disease and Ischemic Stroke Risk During Anticoagulation for Atrial Fibrillation After Cerebral Ischemia. <b>2021</b> , 52, 91-99   | 10 |
| 740 | The Future of Aspirin Therapy in Cardiovascular Disease. <b>2021</b> , 144 Suppl 1, S40-S47   | 0  |
| 739 | [Chronic coronary syndrome : New classification of stable coronary artery disease]. <b>2021</b> , 62, 47-57   | 1  |
| 738 | Anticoagulation dosing in atherosclerotic cardiovascular disease: Is less more?. <b>2021</b> , 83, 8-9  |    |

|     |  |     |
|-----|--|-----|
| 737 | The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. <b>2021</b> , 21, 283-297  | 3   |
| 736 | Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis. <b>2021</b> , 121, 122-130  | 2   |
| 735 | 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <b>2021</b> , 42, 1289-1367   | 920 |
| 734 | Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. <b>2021</b> , 35, 533-538   |     |
| 733 | Immunothrombosis and thromboinflammation in host defense and disease. <b>2021</b> , 32, 314-324  | 26  |
| 732 | Proton pump inhibitors and chronic kidney disease: Reevaluating the evidence from a randomized controlled trial. <b>2021</b> , 30, 4-8   | 3   |
| 731 | Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. <b>2021</b> , 35, 539-547  | 1   |
| 730 | Outcome of acute myocardial infarction versus stable coronary artery disease patients treated with coronary bypass surgery. <b>2021</b> , 53, 70-77  | 3   |
| 729 | Re: Luca Boeri, Paolo Capogrosso, Eugenio Ventimiglia, et al. Clinical Comparison of Holmium Laser Enucleation of the Prostate and Bipolar Transurethral Enucleation of the Prostate in Patients Under Either Anticoagulation or Antiplatelet Therapy. <i>Eur Urol Focus</i> . In press.<br>10.1016/j.euf.2019.03.002: Perioperative Assessment of Transurethral Surgery for Benign Prostatic Obstruction in Patients Taking Oral Anticoagulants or Antiplatelet Agents: A Plea to Improve the Quality of Data. <b>2021</b> , 7, 221-222 |     |
| 728 | [Antithrombotic therapy after peripheral revascularization]. <b>2021</b> , 146, 136-140  | 1   |
| 727 | How to manage patients with polyvascular atherosclerotic disease. Position paper of the International Union of Angiology. <b>2021</b> , 40, 29-41  | 3   |
| 726 | Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry. <b>2021</b> , 9,  | 3   |
| 725 | The association of hemoglobin drop with in-hospital outcomes in COVID-19 patients. <b>2021</b> ,   | 3   |
| 724 | Clinical Effectiveness of Rivaroxaban in Patients With Idiopathic Pulmonary Fibrosis and Thrombosis of the Right Ventricle. <b>2021</b> , 7, 132-157   | 0   |
| 723 | Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery. <b>2021</b> , 71-91  |     |
| 722 | Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. <b>2021</b> , 15, 14   | 1   |
| 721 | Patient-tailored antithrombotic therapy following percutaneous coronary intervention. <b>2021</b> , 42, 1038-1046  | 9   |
| 720 | Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke. <b>2021</b> , 22,   | 7   |

|     |  |   |
|-----|--|---|
| 719 | Guidelines for mono, double and triple antithrombotic therapy. <b>2021</b> , 97, 730-737   | 3 |
| 718 | Kommentar zu den 2020er Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms bei Patienten ohne persistierende ST-Strecken-Hebung. <b>2021</b> , 15, 19-31 | 0 |
| 717 | [Current opportunities for secondary prevention of atherothrombotic stroke]. <b>2021</b> , 121, 97-105   |   |
| 716 | Efficacy and safety of DOACs in patients with peripheral arterial disease: A systematic review and meta-analysis. <b>2021</b> , 29, 846-855  | 1 |
| 715 | Antiplatelet and Anticoagulant Agents. <b>2021</b> , 289-301   |   |
| 714 | Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. <b>2021</b> , 66, 3698-3714   | 0 |
| 713 | Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. <b>2021</b> , 52, 199-208   | 1 |
| 712 | Thrombosis and fibrinolysis in atherosclerotic cardiovascular disease: it takes two to tango. <b>2021</b> ,  |   |
| 711 | Cerebrovascular disease: What is the role of dual antiplatelet therapy for the prevention and treatment of ischemic stroke?. <b>2021</b> , 91-110  | 0 |
| 710 | Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review. <b>2021</b> , 2021, 8886210   | 5 |
| 709 | [The new Epoch of Antithrombotic Therapy in the Long-Term Prevention of a non-Cardioembolic Stroke]. <b>2021</b> , 60, 97-103  |   |
| 708 | Medical and Revascularization Management of Stable Ischemic Heart Disease: An Overview. <b>2021</b> , 30, 83-90  |   |
| 707 | Clinical Indications for Direct Acting Oral Anticoagulants. <b>2021</b> , 9-25   |   |
| 706 | Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <b>2021</b> ,  | 0 |
| 705 | Armarterien. <b>2021</b> , 179-197   |   |
| 704 | Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. <b>2021</b> , 121, 716-730   | 1 |
| 703 | Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. <b>2021</b> , 19, 1001-1017                   | 8 |
| 702 | Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events. <b>2021</b> , 77, 164-169   | 0 |

|     |  |         |
|-----|--|---------|
| 701 | Direct Oral Anticoagulants after Ischemic Stroke: Which Patient? Which Drug? And How Early?. <b>2021</b> , 41, 31-34   | 0       |
| 700 | A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation. <b>2021</b> , 11, 130-141                                       | 1       |
| 699 | New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <b>2021</b> , 319, 51-61                              | 12      |
| 698 | Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease. <b>2021</b> , 37, 2051-2061 | 3       |
| 697 | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis. <b>2020</b> , 11, 608247  | 1       |
| 696 | Anticoagulation Management In Hemodialysis Patients With Atrial Fibrillation: Evidence And Opinion. <b>2021</b> ,  | 2       |
| 695 | Management of Antithrombotic Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 452-460   | 59.2 20 |
| 694 | Combination of Panax notoginseng saponins and aspirin potentiates platelet inhibition with alleviated gastric injury via modulating arachidonic acid metabolism. <b>2021</b> , 134, 111165                       | 11      |
| 693 | Percutaneous Occlusion of the Left Atrial Appendage with Thrombus Irresponsive to Antithrombotic Therapy. <b>2021</b> , 10,  | 1       |
| 692 | The Trend Is Your Friend: Direct Oral Antagonists as Standard Anticoagulants for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Interventions. <b>2021</b> , 77, 162-163                     |         |
| 691 | Cost-Effectiveness of Diagnostic Tools to Establish the Presence of Peripheral Arterial Disease in People with Diabetes. <b>2021</b> ,   | 0       |
| 690 | Antiplatelet and anticoagulation therapy after revascularization for lower extremity artery disease: a national survey and literature overview. <b>2021</b> , 62, 59-70  | 2       |
| 689 | Neues beim Schlaganfall Teil 2: Prävention. <b>2021</b> , 4, 51-66   | 1       |
| 688 | Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 1  | 5       |
| 687 | Features of Antithrombotic Therapy in Patients with Multifocal Arterial Disease. <b>2021</b> , 61, 87-95   | 1       |
| 686 | Antithrombotic therapy in diabetes: which, when, and for how long?. <b>2021</b> , 42, 2235-2259  | 8       |
| 685 | Ischemic Stroke and Heart Failure: Facts and Numbers. An Update. <b>2021</b> , 10,   | 3       |
| 684 | Abnormal vascular physiology in the lower extremities as a risk factor for ischemic stroke and mortality. <b>2021</b> , 121, 463-470   | 0       |

|     |   |    |
|-----|---|----|
| 683 | Myocardial Infarction Complicated by Ischemic Stroke: Risk Factors, Prognosis, Unresolved Problems and Possible Methods of Prevention. <b>2021</b> , 17, 73-82  |    |
| 682 | The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 52, 904-913 | 2  |
| 681 | Cancer and Embolic Stroke of Undetermined Source. <b>2021</b> , 52, 1121-1130   | 14 |
| 680 | Rivaroxaban reduces thromboxane induced platelet aggregation - the forgotten compass arm?. <b>2021</b> , 32, 1126-1128  | 1  |
| 679 | Low-Dose Anticoagulation for Atrial Fibrillation: When Is a Floor a Trap Door?. <b>2021</b> , 77, 1208-1210   |    |
| 678 | Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. <b>2021</b> , 41, 459-468  | 1  |
| 677 | Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. <b>2021</b> , 32, 1474-1483                                       | 17 |
| 676 | What internist can do for the patient after the ischemic stroke. <b>2021</b> , 67, 7-14   | 1  |
| 675 | Prognostic value of stress cardiovascular magnetic resonance in asymptomatic patients with known coronary artery disease. <b>2021</b> , 23, 19  | 6  |
| 674 | Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review. <b>2021</b> , 41, 353-369  | 3  |
| 673 | Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <b>2021</b> , 110, 1554-1563  | 4  |
| 672 | Precision Treatment in ACS-Role of Assessing Fibrinolysis. <b>2021</b> , 10,  | 0  |
| 671 | The Management of Coronary Artery Disease in Ethiopia: Emphasis on Revascularization. <b>2021</b> , 31, 439-454   |    |
| 670 | The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. <b>2021</b> , 61, 1010-1026  | 2  |
| 669 | Pharmacotherapy in Stable Coronary Artery Disease: Historical Perspectives and New Insights from the ISCHEMIA Trial. <b>2021</b> , 16, e04  |    |
| 668 | Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. <b>2021</b> , 77, 1197-1207   | 10 |
| 667 | Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction.. <b>2021</b> , 2, 233-242  |    |
| 666 | Prevention and Management of Urgent/Emergent Limb Ischemia. <b>2021</b> , 23, 41  | 1  |

|     |   |    |
|-----|---|----|
| 665 | Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. <b>2021</b> , 5, 100144   | 2  |
| 664 | Prevenzione secondaria nella malattia coronarica. <b>2021</b> , 23, 1-11  | 0  |
| 663 | Managing the coagulation system in patients with arterial disease. <b>2021</b> , 73, 940-941  |    |
| 662 | The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease. <b>2021</b> , 321, 1-7   | 1  |
| 661 | Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. <b>2021</b> , 10,   | 0  |
| 660 | Long-term prognostic value of stress perfusion cardiovascular magnetic resonance in patients without known coronary artery disease. <b>2021</b> , 23, 43  | 1  |
| 659 | Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association. <b>2021</b> , 143, e875-e891   | 12 |
| 658 | Disparities Between International Guidelines (AHA/ESC/ESVS/ESVM/SVS) Concerning Lower Extremity Arterial Disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE). <b>2021</b> , 72, 1-56 | 8  |
| 657 | Akutes Koronarsyndrom ohne persistierende ST-Streckenhebung [Was ist neu in den 2020-Leitlinien der ESC?]. <b>2021</b> , 10, 105-111  | 0  |
| 656 | Effects of Acute Coronary Syndrome and Stable Coronary Artery Disease on Bleeding and Ischemic Risk After Percutaneous Coronary Intervention. <b>2021</b> , 85, 1928-1941   | 1  |
| 655 | Oral anticoagulation and outcomes in patients with acute myocardial infarction: Insights from the Hungarian Myocardial Infarction Registry. <b>2021</b> , 75, e14179  | 0  |
| 654 | MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review. <b>2021</b> , 12, 652579   | 6  |
| 653 | The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. <b>2021</b> , 14, 796-802  | 0  |
| 652 | Antithrombotic Management of Elderly Patients With Coronary Artery Disease. <b>2021</b> , 14, 723-738   | 5  |
| 651 | Detection of asymptomatic carotid stenosis in patients with lower-extremity arterial disease: development and external validations of a risk score. <b>2021</b> , 108, 960-967  | 2  |
| 650 | Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction. <b>2021</b> , 9, 243-253   | 4  |
| 649 | Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis. <b>2021</b> , 77, 450-457   |    |
| 648 | Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison. <b>2021</b> , 1-6   | 2  |



|     |   |    |
|-----|---|----|
| 647 | Fibrinolysis in Acute and Chronic Cardiovascular Disease. <b>2021</b> , 47, 490-505   | 6  |
| 646 | Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. <b>2021</b> , 14, 768-780   | 2  |
| 645 | NSTE-ACS: Medikamentöse Therapie   Antithrombotische Therapie. <b>2021</b> , 10, 128-132  |    |
| 644 | An Individual-Level Meta-Analysis Using Real-World and Pivotal Studies on Mortality From the Use of Paclitaxel-Containing Devices in Japanese Femoropopliteal Disease Patients. <b>2021</b> , 85, 2137-2145                     | 2  |
| 643 | Partitioning risk factors for embolic stroke of undetermined source using exploratory factor analysis. <b>2021</b> , 17474930211009847  | 2  |
| 642 | Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. <b>2021</b> , 41, 365-387   | 0  |
| 641 | The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents. <b>2021</b> , 98, E332-E341                           |    |
| 640 | Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study. <b>2021</b> , 10, e019644  | 3  |
| 639 | Anticoagulants. 1-45  |    |
| 638 | The 70/30 Rule Between Men and Women-Disparity or Opportunity?-Reply. <b>2021</b> , 6, 482-483  |    |
| 637 | 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <b>2021</b> , 23, 1612-1676   | 99 |
| 636 | Medical management of risk factors for vascular disease. <b>2021</b> , 39, 248-256  |    |
| 635 | Aspirin at 120: Retiring, recombining, or repurposing?. <b>2021</b> , 5, e12516   | 2  |
| 634 | What Could be the Most Advantageous Therapeutic Approach to Avoid both Arterial and Venous Thrombosis in Hyperhomocysteinemia?. <b>2021</b> , 17, 171-172   | 2  |
| 633 | Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study. <b>2021</b> , 97, e436-e443   | 1  |
| 632 | Antithrombotic regimens in females with symptomatic lower extremity peripheral arterial disease: protocol for a systematic review and meta-analysis. <b>2021</b> , 11, e042980  |    |
| 631 | Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. <b>2021</b> , 20, 2847 | 1  |
| 630 | Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. <b>2021</b> ,  | 0  |

|     |   |    |
|-----|---|----|
| 629 | 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. <b>2021</b> , 26, 4449  | 22 |
| 628 | Troponin Elevation After Ischemic Stroke and Future Cardiovascular Risk: Is the Heart in the Right Place?. <b>2021</b> , 10, e021474  | 0  |
| 627 | High-Sensitivity Cardiac Troponin Predicts Major Cardiovascular Events in Diabetic Patients With Critical Limb Ischemia and Foot Lesions. <b>2021</b> , 8, 595701                     | 1  |
| 626 | Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy. <b>2021</b> , 17, 294-305   | 2  |
| 625 | Considerations for use of direct oral anticoagulants in arterial disease. <b>2021</b> , 5,  | 0  |
| 624 | Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. <b>2021</b> , 17, 521-534  | 1  |
| 623 | Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <b>2021</b> , 235, 12-23 | 14 |
| 622 | Canakinumab for secondary prevention of coronary artery disease. <b>2021</b> , 17, 427-442  | 2  |
| 621 | Interplay between inflammation and thrombosis in cardiovascular pathology. <b>2021</b> , 18, 666-682  | 56 |
| 620 | Early stopping of a randomised trial for efficacy: a medical, ethical and regulatory challenge. <b>2021</b> , 107, 1109-1110  | 1  |
| 619 | Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <b>2021</b> , 107, 1130-1137                          | 0  |
| 618 | Do we have a unified consensus on antithrombotic management of PAD?. <b>2021</b> , 40, 229-239  | 0  |
| 617 | Thrombosis: Grand Challenges Ahead!. <b>2021</b> , 8, 637005  | 1  |
| 616 | Lower Extremity Arterial Disease as a Predictor of Incident Atrial Fibrillation and Cardiovascular Events. <b>2021</b> , 96, 1175-1183  | 1  |
| 615 | EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <b>2021</b> , 6-61  | 2  |
| 614 | Prevention of cardiovascular events in patients with stable coronary artery disease: myocardial revascularization or pharmacological treatment?. <b>2021</b> , 20, 2888               |    |
| 613 | Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <b>2021</b> ,   | 1  |
| 612 | Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. <b>2021</b> ,              | 0  |

|     |  |     |
|-----|--|-----|
| 611 | Antiplatelet therapy with or without anticoagulant therapy for lower extremity peripheral artery disease: A systematic review. <b>2021,</b>  |     |
| 610 | Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis. <b>2021,</b>  | 4   |
| 609 | Optimal Medical Management of Asymptomatic Carotid Stenosis. <b>2021,</b> 52, 2191-2198  | 1   |
| 608 | Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. <b>2021,</b> 26, 415-428  |     |
| 607 | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <b>2021,</b> 10,  | 1   |
| 606 | Comments on the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <b>2021,</b> 74, 482-487  |     |
| 605 | Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. <b>2021,</b> 74, 544.e1-544.e73   | 1   |
| 604 | Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. <b>2021,</b> 1   | 1   |
| 603 | Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management. <b>2021,</b> 74, 2030-2039.e2   | 1   |
| 602 | Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <b>2021,</b> 397, 2253-2263 | 150 |
| 601 | Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD. <b>2021,</b> 128, 1885-1912   | 12  |
| 600 | Prognostic Value of Vasodilator Stress Perfusion Cardiovascular Magnetic Resonance in Patients With Prior Myocardial Infarction. <b>2021,</b> 14, 2138-2151  | 1   |
| 599 | Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection. <b>2021,</b> 27, 2112-2130   | 7   |
| 598 | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update. <b>2021,</b> 8, 660986   | 1   |
| 597 | How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <b>2021,</b>                                    |     |
| 596 | Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <b>2021,</b> 10, e018684   | 3   |
| 595 | Comentarios a la guía ESC 2020 sobre el tratamiento del síndrome coronario agudo sin elevación del segmento ST. <b>2021,</b> 74, 482-487   |     |
| 594 | Reply: All Fat Is Not Created Equal: The Problem of Defining Obesity in the Elderly. <b>2021,</b> 77, 2757   |     |

- 593 Residual Recurrence Risk of Ischemic Cerebrovascular Events: Elements and Implications. **2021**, 37, 1361-1364
- 592 Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons. **2021**, 36, 609-615 0
- 591 Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease. **2021**, 28, 573-583 1
- 590 Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation. **2021**, 12, 614762 0
- 589 Treat young and expect to live or treat when expecting to leave? Moving towards lifetime-guided benefit strategies in cardiovascular prevention. **2021**,
- 588 Prevenci3 secundaria en el paciente coronario. **2021**, 25, 1-12
- 587 Stroke risk associated with carotid and aortic atherosclerosis in patients with atrial fibrillation: A systematic review. **2021**, 425, 117444 1
- 586 The Role of Colchicine in Atherosclerotic Cardiovascular Disease. **2021**, 30, 795-806 7
- 585 What Is the Clinical Impact of Stress CMR After the ISCHEMIA Trial?. **2021**, 8, 683434 0
- 584 Long-Term Prognostic Value of Stress Cardiovascular Magnetic Resonance in Patients With History of Percutaneous Coronary Intervention. **2021**, 14, e012374 2
- 583 Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. **2021**, 181, 817-824 15
- 582 Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia: A Review. **2021**, 325, 2188-2198 17
- 581 Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. **2021**, 19, 2322-2334 2
- 580 Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. **2021**, 19, 2583-2595 0
- 579 Remote history of VTE is associated with severe COVID-19 in middle and older age: UK Biobank cohort study. **2021**, 19, 2533-2538 1
- 578 The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery. **2021**, 1 0
- 577 Elderly patient with atrial fibrillation and coronary risks. **2021**, 51-57
- 576 Antithrombotic Therapy to Reduce Mortality in Patients With Atherosclerosis: 2 Pathways to a Single Goal. **2021**, 78, 24-26 0

|     |  |    |
|-----|--|----|
| 575 | Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model. <b>2021</b> , 8, 690476   | 1  |
| 574 | Optimale medikamentöse Therapie bei Typ-2-Diabetikern mit einer koronaren Herzerkrankung □ Update 2021. <b>2021</b> , 35, 201-210  |    |
| 573 | Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. <b>2021</b> , 3, 195-205  |    |
| 572 | Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <b>2021</b> , 144, 74-84   | 9  |
| 571 | Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study. <b>2021</b> , 75, e14597  | 0  |
| 570 | Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis. <b>2021</b> , 89-105  | 1  |
| 569 | Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement. <b>2021</b> , 42, 1566-1575  | 6  |
| 568 | Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS) and the Pan-American College of Endothelium (PACE). <b>2021</b> , | 1  |
| 567 | Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. <b>2021</b> , 117, 181-264  | 7  |
| 566 | Yin-xing-tong-mai decoction attenuates atherosclerosis via activating PPARELXR/ABCA1/ABCG1 pathway. <b>2021</b> , 169, 105639  | 7  |
| 565 | Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <b>2021</b> , 78, 14-23  | 9  |
| 564 | Endovascular Relining of Chronically Occluded Infrainguinal Venous Bypass Grafts. <b>2021</b> , 74, 339-343  | 1  |
| 563 | The challenge of choosing in cardiovascular risk management. <b>2021</b> , 1   | 0  |
| 562 | Antithrombotische Therapie bei Diabetes mellitus. 1  |    |
| 561 | Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. <b>2021</b> , 22,   | 2  |
| 560 | Development of Molecular Magnetic Resonance Imaging Tools for Risk Stratification of Carotid Atherosclerotic Disease Using Dual-Targeted Microparticles of Iron Oxide. <b>2021</b> , 1   | 1  |
| 559 | Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. <b>2021</b> , 3, 936-949  | 0  |
| 558 | Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. <b>2021</b> , 42, 4013-4024  | 16 |

|     |   |     |
|-----|---|-----|
| 557 | 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <b>2021</b> , 52, e364-e467   | 201 |
| 556 | [Antiplatelet therapy and anticoagulation in patients with coronary heart disease]. <b>2021</b> , 146, 1041-1050  | 1   |
| 555 | Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <b>2021</b> , 144, 1104-1116   | 2   |
| 554 | Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <b>2021</b> , 331, 38-44  |     |
| 553 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <b>2021</b> , 42, 3227-3337  | 358 |
| 552 | Renal function and outcome of patients with non-valvular atrial fibrillation. <b>2021</b> ,   |     |
| 551 | Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics. <b>2021</b> , 1   | 3   |
| 550 | Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options. <b>2021</b> , 1   | 1   |
| 549 | Vascular endothelial Tissue Factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. <b>2021</b> ,  | 9   |
| 548 | Edoxaban in cardiovascular disease management: Review. <b>2021</b> ,  | 0   |
| 547 | Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation cOroNavirus)-Coalition IV trial. <b>2021</b> , 238, 1-11 | 10  |
| 546 | Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis. <b>2021</b> , 2021, 8561350                     | 0   |
| 545 | Anticoagulants for stroke prevention in heart failure with reduced ejection fraction. <b>2021</b> , 1   | 1   |
| 544 | Evolution of Antithrombotic Management of Atrial Fibrillation After Percutaneous Coronary Intervention Over 10 Years and Guidelines Uptake. <b>2021</b> , 3, 1025-1032  | 2   |
| 543 | Risk stratification of cardiovascular complications using CHADS-VASc and CHADS scores in chronic atherosclerotic cardiovascular disease. <b>2021</b> , 337, 9-15  | 0   |
| 542 | The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants. <b>2021</b> , 22,  | 5   |
| 541 | Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors. <b>2021</b> , 6, 918-925   | 0   |
| 540 | Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. <b>2021</b> , 62, 654-655   | 0   |

|     |   |    |
|-----|---|----|
| 539 | The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids. <b>2021</b> , 76, 2690-2696   | 5  |
| 538 | Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <b>2021</b> , 42, 4040-4048  | 3  |
| 537 | Ischemic Stroke. <b>2021</b> ,  | 22 |
| 536 | Myocardial Injury After Colorectal Cancer Surgery and Postoperative 90-Day Mortality and Morbidity: A Retrospective Cohort Study. <b>2021</b> , 64, 1531-1541   | 1  |
| 535 | The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis. <b>2021</b> , 77, 1485-1494  |    |
| 534 | Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <b>2021</b> ,  | 1  |
| 533 | Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. <b>2021</b> , 140, 111783  |    |
| 532 | "Novel Clinical Concepts in Thrombosis": Integrated Care for Stroke Management-Easy as ABC. <b>2021</b> ,   | 7  |
| 531 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <b>2021</b> ,  | 31 |
| 530 | Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. <b>2021</b> , 64, 2701-2712 | 1  |
| 529 | Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. <b>2021</b> , 10, e020330  | 1  |
| 528 | Extended antithrombotic therapy for secondary prevention of cardiovascular events: A tool for pharmacists.. <b>2022</b> , 155, 12-17  |    |
| 527 | Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention. <b>2021</b> , 13, 813-823  | 2  |
| 526 | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <b>2021</b> , 17, 628-637  |    |
| 525 | Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <b>2021</b> , 10, e020446   | 1  |
| 524 | Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial. <b>2021</b> ,  | 10 |
| 523 | Aortic plaque burden predicts vascular events in patients with cardiovascular disease: The EAST-NOGA study. <b>2022</b> , 79, 144-152   | 1  |
| 522 | Lesson learned from the COMPASS and VOYAGER PAD trials: dual pathway inhibition as a new antithrombotic paradigm?. <b>2021</b> ,  |    |

|     |   |   |
|-----|---|---|
| 521 | Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid. <b>2021</b> , 1  | 1 |
| 520 | Net clinical benefit of a reduced dose of DOACs in non-valvular atrial fibrillation: A meta-analysis of randomized trials. <b>2021</b> , 175, 105902  |   |
| 519 | Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. <b>2022</b> , 243, 54-65   |   |
| 518 | Platelet GPVI (Glycoprotein VI) and Thrombotic Complications in the Venous System. <b>2021</b> , 41, 2681-2692  | 2 |
| 517 | Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. <b>2021</b> , 29, 525-535                          | 1 |
| 516 | The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy. <b>2021</b> , 21, 466 | 0 |
| 515 | An update of the efficacy and comparative characteristics of direct (new) oral anticoagulants (DOACs). <b>2021</b> ,  | 0 |
| 514 | The CHADS-VASc Score for Risk Stratification of Stroke in Heart Failure With-vs-Without Atrial Fibrillation. <b>2021</b> , 155, 72-77   | 0 |
| 513 | Pharmacological management of obstructive peripheral arterial disease: two case reports. <b>2021</b> , 1-5  |   |
| 512 | Eurasian Guidelines for the diagnostics and management of stable coronary artery disease (2020-2021). <b>2021</b> , 54-93   |   |
| 511 | Eighty years of oral anticoagulation: Learning from history. <b>2021</b> , 141, 106918  | 1 |
| 510 | The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. <b>2021</b> , 13,  | 5 |
| 509 | Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. <b>2021</b> , 62, 439-449    | 1 |
| 508 | Thrombus Structural Composition in Cardiovascular Disease. <b>2021</b> , 41, 2370-2383  | 8 |
| 507 | Effects of Anticoagulation on Low-Density Lipoprotein-Cholesterol and Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation. <b>2021</b> , 134, e533   |   |
| 506 | Characteristics of atherosclerosis in femoropopliteal artery and its clinical relevance. <b>2021</b> , 335, 31-40   | 1 |
| 505 | Standardized Assessment of Global activities in the Elderly scale in adult cardiac surgery patients. <b>2021</b> , 127, 539-546   | 1 |
| 504 | Peripheral Artery Disease. <b>2022</b> , 495-504  |   |



503 Peripheral Arterial Disease. **2021**, 365-379

502 Peripheral arterial disease – different kind of arterial disease? The role of antiplatelet therapy in the prevention and treatment of limb ischemia. **2021**, 79-89

501 Venous Thromboembolism in Heart Failure Patients: Building Evidence towards Better Care and the Need for Precision. **2021**, 51, 781-783

500 Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. **2021**, 143, 372-388 22

499 Mejorar la prevenci3n de la trombosis y las complicaciones cardiovasculares durante la pandemia de COVID-19. **2021**, 21, 1-8

498 Assessment of the relationship between death and CHA2DS2-VASc score in peripheral artery disease. **2020**, 39, 509-516 5

497 [Detection of peripheral artery disease in patients with ischemic heart disease. A quick guide for medical practitioners]. **2021**, 60, 125-132

496 Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban. **2020**, 8, 127-131 1

495 Antithrombotika und Antih3orrhagika. **2019**, 531-555 3

494 Clinical trial results - A closer look under the surface. **2020**, 75, 21-22 1

493 Incidence and predictors of stroke in patients discharged with the diagnosis of acute coronary syndrome. **2019**, 276, 20-25 6

492 Long-Term Evolution of Premature Coronary Artery Disease. **2019**, 74, 1868-1878 26

491 Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy. **2020**, 213, 107584 12

490 Aspirin for secondary prevention of cardiovascular disease. **2020**, 395, 1462-1463 6

489 Antithrombotic treatment in peripheral artery disease. **2018**, 47, 99-108 20

488 ESVM Guideline on peripheral arterial disease. **2019**, 48, 1-79 46

487 5 Conservative treatment for PAD - Risk factor management. **2019**, 48, 1-12 6

486 Symptomatische und asymptomatische Karotisstenose: leitlinienbasierte Therapie. **2020**, 07, 233-246 0

|     |   |    |
|-----|---|----|
| 485 | Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. <b>2020</b> , 07, 291-301  | 1  |
| 484 | Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <b>2020</b> , 46, 908-918  | 4  |
| 483 | Diabetes Mellitus And Outcomes Of Lower Extremity Revascularization For Peripheral Artery Disease. <b>2020</b> ,  | 1  |
| 482 | Evidence-Based Medical Management of Peripheral Artery Disease. <b>2020</b> , 40, 541-553   | 26 |
| 481 | Sex-Specific Platelet Activation Through Protease-Activated Receptors Reverses in Myocardial Infarction. <b>2021</b> , 41, 390-400  | 4  |
| 480 | Is there a role for low-dose DOACs as prophylaxis?. <b>2019</b> , 2019, 187-193   | 2  |
| 479 | Diabetes mellitus type 2 in adults. <b>2020</b> , 23, 4-102   | 9  |
| 478 | Thrombin generation and fibrin clot structure after vitamin D supplementation. <b>2019</b> , 8, 1447-1454   | 10 |
| 477 | Direct-acting Anticoagulants in Chronic Coronary Syndromes. <b>2020</b> , 15, 1-7   | 1  |
| 476 | Comorbidities in clinical practice. Algorithms for diagnostics and treatment. <b>2019</b> , 18, 5-66  | 86 |
| 475 | 2020 Clinical practice guidelines for Stable coronary artery disease. <b>2020</b> , 25, 4076  | 50 |
| 474 | 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. <b>2020</b> , 25, 4103  | 59 |
| 473 | [Contemporary approaches to determine the duration of anticoagulant therapy for venous thromboembolism]. <b>2019</b> , 94-103   | 4  |
| 472 | [Treatment of Patients with Stable Manifestations of Atherosclerotic Vascular Disease: New Possibilities (Conclusion of the Council of Experts from November 16, 2018, Rostov-on-Don)]. <b>2019</b> , 59, 97-100        | 2  |
| 471 | Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature. <b>2018</b> , 6, 323       | 10 |
| 470 | Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies Used for Diabetic Patients in Primary and Secondary Prevention. <b>2020</b> , 26, 2780-2788 | 7  |
| 469 | Antithrombotic Therapy in Carotid Artery Disease. <b>2020</b> , 26, 2725-2734   | 1  |
| 468 | The Role of Antithrombotic Therapy in Heart Failure. <b>2020</b> , 26, 2735-2761  | 0  |

|     |  |     |
|-----|--|-----|
| 467 | High Risk of One-year Stroke Recurrence in Patients with Younger Age and Prior History of Ischemic Stroke. <b>2019</b> , 16, 250-257   | 5   |
| 466 | Novel Direct Anticoagulants and Atherosclerosis. <b>2019</b> , 17, 29-34   | 2   |
| 465 | Technical improvements in carotid revascularization based on the mechanism of procedural stroke. <b>2019</b> , 60, 313-324   | 2   |
| 464 | Non-vitamin K oral anticoagulants for coronary or peripheral artery disease: a systematic review and meta-analysis of mortality and major bleeding. <b>2019</b> , 67, 477-486  | 5   |
| 463 | [Therapeutic aspects of the choice of antithrombotic therapy in patients with multifocal lesions of peripheral arteries]. <b>2019</b> , 91, 158-164  | 2   |
| 462 | Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <b>2020</b> , 14, 998   | 2   |
| 461 | EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). <b>2020</b> , 4-77   | 9   |
| 460 | Current status of rivaroxaban in elderly patients with pulmonary embolism (Review). <b>2020</b> , 19, 2817-2825  | 5   |
| 459 | Rivaroxaban treatment for young patients with pulmonary embolism (Review). <b>2020</b> , 20, 694-704   | 2   |
| 458 | 2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction. <b>2020</b> , 50, 845-866   | 6   |
| 457 | Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. <b>2019</b> , 67, 1200-1212  | 3   |
| 456 | Quo vadis, aspirin?. <b>2018</b> , 14, e1153-e1157   | 1   |
| 455 | Trials of antithrombotic therapy in percutaneous coronary intervention: what evidence do we need to optimise our practice?. <b>2018</b> , 14, 19-23  | 2   |
| 454 | 2018 ESC/EACTS Guidelines on myocardial revascularization. <b>2019</b> , 14, 1435-1534   | 180 |
| 453 | EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. <b>2020</b> , 15, 1133-1180   | 82  |
| 452 | Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. <b>2020</b> , 27, 809-907 | 16  |
| 451 | Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <b>2020</b> , 27, 661-676   | 4   |
| 450 | An evaluation of rivaroxaban and clopidogrel in a rat lower extremity ischemia-reperfusion model: An experimental study. <b>2019</b> , 27, 513-520   | 3   |

- 449 Antithrombotic Treatment for Symptomatic Peripheral Artery Disease. **2019**, 35, 557-562 2
- 448 Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. **2020**, 9, 2
- 447 Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction. **2021**, 6, 749-761 0
- 446 A Brief Overview of Medical Management Options in Peripheral Arterial Disease. 0
- 445 The impact of atrial fibrillation and stroke risk factors on left atrial blood flow characteristics. **2021**, 2, 2
- 444 Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. **2021**, 23, 77 0
- 443 A protocol for DUAL pathway inhibition (low-dose rivaroxaban and aspirin) as compared to aspirin only to improve endothelial function in peripheral artery disease. **2021**, 2, e0163 0
- 442 Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. **2021**, 345, 7-13 13
- 441 [Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?]. **2021**, 62, 1243-1252 0
- 440 Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis. **2021**, 19, 69 0
- 439 Coronary Artery Disease in Patients Older than 35 and Eligible for Cardiovascular Secondary Prevention: An Italian Retrospective Observational Analysis of Healthcare Administrative Databases. **2021**, 10, 0
- 438 Prevention of ischaemic events in subjects with polydistrict vascular disease. **2021**, 23, E103-E108 0
- 437 Residual Cardiovascular Risk Factors in Dyslipidemia. 0
- 436 Neues beim Schlaganfall: Prävention. **2021**, 3, 291-306 0
- 435 Of Life and Limb: Addition of Low-Dose Rivaroxaban for Secondary Prevention After Peripheral Artery Disease Surgery. **2021**, 144, 1117-1119 0
- 434 On Isolated Systolic Hypertension and Combined Antithrombotic Therapy. **2021**, 0
- 433 Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association. **2021**, 144, e287-e305 9
- 432 Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease. **2021**, 0

431 Management of stroke in patients on antithrombotic therapy: Practical issues in the era of direct oral anticoagulants. **2021**,

430 Long-Term (7-Year) Clinical Implications of Newly Unveiled Asymptomatic Abnormal Ankle-Brachial Index in Patients With Coronary Artery Disease. **2021**, 10, e021587

429 Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. **2021**, 1-8

428 Medical Management of Peripheral Artery Disease. **2021**, 39, 471-482

o

427 Peripheral Arterial Disease. **2017**,

426 Endeavours to define optimal antithrombotic therapy after percutaneous coronary intervention. **2017**, 13, e1386-e1391

425 Do we have to change therapeutic considerations in peripheral arterial disease?. **2018**, 47, 5-6

1

424 Acute cerebrovascular syndrome. **2018**, 29, 318-324

423 The year in cardiology 2017: prevention. **2018**, 13, 79-98

422 Coronary heart disease: how to improve the effectiveness of treatment?. **2018**, 46-52

421 . **2018**, 58, 35-40

420 CLINICAL IMPRESSION: PLANNED PERCUTANEOUS CORONARY INTERVENTION IN A PATIENT WITH ATRIAL FIBRILLATION. **2018**, 92-102

419 Intervención coronaria en pacientes con fibrilación auricular. **2019**, 18, 15-20

418 Conclusiones y recomendaciones prácticas. **2019**, 18, 34-40

417 Guidelines on the diagnosis and treatment of diabetic foot. **2019**, 2, 55

416 Antiplatelet agent plus small dose of anticoagulant for atherosclerotic vascular diseases—COMPASS trial. **2019**, 30, 815-827

415 Understanding of pathophysiology of thrombosis and prediction of the efficacy of medicine using simulation approach. **2019**, 30, 856-861

414 The Impact of Antithrombotic Regimens on Clinical Outcomes After Endovascular Intervention and Bypass Surgery for Infrapopliteal Artery Disease. **2019**, 10, 255-267

- 413 2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants. **2019**, 94, 57-82 1
- 412 Selecció de lo mejor del añ 2018 en cardiologí clíica. **2019**, 54, 16-22
- 411 Management of diabetic patients with lower extremity peripheral arterial disease. **2019**, 65, 326-334
- 410 [Peripheral arterial disease (PAD) medical treatment: Megalomania?]. **2019**, 44, 181-183
- 409 (Secondary prevention of coronary heart disease and peripheral artery disease combining antiaggregation and anticoagulation therapy. Expert consensus statement of the Czech Society of Cardiology, the Czech Society of Internal Medicine and the Czech Society of Angiology to the outcomes of COMPASS trial). **2019**, 61, e334-e340
- 408 Evaluation of Thrombin Generation in Patients with Stable Coronary Artery Disease with a Prior Myocardial Infarction. **2019**, 6, 37-45 1
- 407 Cardioembolic stroke, the basis of diagnosis and prevention. **2019**, 55-58 0
- 406 Antithrombotic therapy of coronary heart disease: time - tested essential principles. **2019**, 91, 19-24
- 405 Atherothrombotic stroke in non-valvular atrial fibrillation. **2019**, 11, 78-81 1
- 404 Anticoagulation in addition to dual antiplatelet therapy has no impact on long-term follow-up after endovascular treatment of (sub)acute lower limb ischemia. **2019**, 48, 321-329 1
- 403 Non vitamin K oral anticoagulants versus antiplatelets in embolic stroke of undetermined source: most updated evidence. **2019**, 67, 340-347 1
- 402 Korean Heart Rhythm Society 2019 Practical Guidelines on Antithrombotic Therapy for AF Patients Undergoing Percutaneous Coronary Intervention or Structural Heart Disease Intervention. **2019**, 94, 330-342
- 401 Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation. **2019**, 21, 259-275 2
- 400 The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease. **2019**, 34-41
- 399 Saving lives, saving limbs: tackling the global pandemic of peripheral arterial disease. **2019**, 26,
- 398 Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment?. **2019**, 15, 289-299
- 397 Thromboseneigung. **2020**, 1-9
- 396 Patient with Polyvascular Atherosclerosis Acutely Complicated with Different Major Vascular Events. 75-80

- 395 Sekundární prevalence ischemických chorob srdce a chorob periferních tepen kombinací antiagregační a antikoagulační léčby. Odborná stanovisko Česká kardiologická společnost, Česká internistická společnost a S. J. E. Purkyně a Česká angiologická společnost a S. J. E. Purkyně v rámci studie COMPASS. **2019**, 65, 704-710
- 394 CHANGES IN THE HEMOSTATIC SYSTEM AGAINST THE BACKGROUND OF VARIOUS TREATMENT REGIMENS IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES. **2019**, 6, 49-59
- 393 Dabigatran in patients with myocardial injury after non-cardiac surgery. Report on the MANAGE Trial. **2019**, 66, 455-458
- 392 Chronische arterielle Verschlusskrankheit. **2020**, 49-76
- 391 Chronic Coronary Syndromes – the ESC Redefines the Concept of Stable Coronary Artery Disease. **2019**, 4, 177-180
- 390 Diagnosis and treatment of stable coronary heart disease in the practice of a family doctor. **2019**, 2019, 63-68
- 389 Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease. **2019**, 76-86 1
- 388 Antithrombotika und Antihämorrhagika. **2020**, 395-420
- 387 Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model. **2020**,
- 386 Emerging clinical setting of direct oral anticoagulants: atherothrombotic events prevention. **2020**, 21, 1-5
- 385 [Risk of Coronary Events in Atrial Fibrillation]. **2020**, 60, 43-52
- 384 Rivaroxaban in COMPASS trial. **2020**, 66, 197-198
- 383 New oral anticoagulants - possible extension to other indications (Review). **2020**, 20, 2401-2405 3
- 382 Non-vitamin K antagonist oral anticoagulants and sport. **2020**, 68, 98-109 0
- 381 Add-On Therapies in Cardiovascular Disease: Reviewing ICER’s Report and the Potential Effect on Payers. **2020**, 26, 786-788
- 380 Management of ischemic risk events in patients with multifocal atherosclerosis and type 2 diabetes mellitus. **2020**, 34-44
- 379 [The balance of benefit and risk in prescribing antithrombotic therapy for patients with coronary artery disease. How to deal with the gastrointestinal bleeding problem?]. **2020**, 60, 115-124
- 378 Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. **2020**, 13, 695-706 2

- 377 A COMPASS for VOYAGERS with revascularized peripheral artery disease. **2020**, 49, 427-428
- 376 Extended antithrombotic therapy in secondary prevention: "There is no such thing as a free lunch" **2020**, 39, 503-504
- 375 The effect of rivaroxaban low doses on the stable angina of the II-III functional class clinical manifestations and the quality of life in patients with ischemic heart disease. **2021**, 61, 47-51
- 374 Antithrombotic therapy for chronic ischemic heart disease: how to balance risk and benefit in different categories of patients?. **2020**, 76-94
- 373 Use of cardiovascular imaging in risk restratification of the diabetic patient. **2021**, 28, 122-133 1
- 372 Antiplatelet Therapy. **2021**, 249-288
- 371 Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. **2020**, 26, 5953-5968 0
- 370 New Possibilities to Reduce the Residual Risk in Patients with Ischemic Heart Disease. **2020**, 60, 1370 1
- 369 Independent Impact of Peripheral Artery Disease on Percutaneous Coronary Intervention. **2020**, 9, e017655 2
- 368 Antiplatelet therapy in secondary prevention of non-embolic ischaemic stroke. **2020**, 66, 501-506
- 367 Sekundärprävention. **2020**, 149-181
- 366 Stable Ischemic Heart Disease. **2020**, 19-39
- 365 A new era of medical therapy for peripheral artery disease. **2020**, 19, e20190056 1
- 364 Thromboseneigung. **2020**, 37-45
- 363 Prospects of rivaroxaban application in treatment of patients with chronic ischemic heart disease. **2020**, 44-50
- 362 [Current concepts of anticoagulant and antiplatelet therapy in patients with vascular pathology]. **2020**, 26, 16-26 0
- 361 Current and Emerging Therapies for Atherosclerosis. **2020**, 71-88
- 360 [Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]. **2020**, 60, 131-141



- 359 Latent opportunities for the prevention of ischemic stroke in patients with atherosclerosis-related diseases: additional analysis of randomized trials on rivaroxaban. **2020**, 25, 81-89
- 358 Medical Management for Secondary Stroke Prevention. **2020**, 26, 435-456 3
- 357 Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. **2021**, 338, 55-63 0
- 356 Place des anticoagulants dans l'artéropathie oblitérante des membres inférieurs. **2021**,
- 355 Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis. **2021**, 81, 2003-2016 0
- 354 Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands. **2021**, 24, 1231-1239 0
- 353 Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines. **2021**, 17, 761-770
- 352 Excess Mortality in Aspirin and Dipyron (Metamizole) Co-Medicated in Patients With Cardiovascular Disease: A Nationwide Study. **2021**, 10, e022299 1
- 351 Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects. **2021**, 14, 7797-7805 0
- 350 Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. **2021**, 50, 401-411 4
- 349 CONCERNING NEW STANDARDS OF TREATMENT OF THE PERIPHERAL ARTERIES DISEASES ON BACKGROUND OF MODERN RECOMMENDATIONS AND DATA OF CLINICAL INVESTIGATIONS, TAKING INTO ACCOUNT A SIGNIFICANCE OF PROPHYLAXIS OF UNFAVORABLE EVENTS WITH THE EXTREMITY AND CARDIO-VA. **2020**, 87, 102-104
- 348 Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?. **2020**, 16, 465-473
- 347 Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment. **2020**, 113, 585-592
- 346 Modern Approaches to Optimal Antithrombotic Therapy for Stable Ischemic Heart Disease. **2020**, 10, 348-356
- 345 Primärprävention des Schlaganfalls. **2020**, 39, 636-643
- 344 Up-to-date potential of antithrombotic therapy in patients with coronary artery disease and diabetes. **2020**, 25, 4077
- 343 Perioperative troponin screening and detection of myocardial injury. **2021**, 59, 1-8 0
- 342 Anticoagulation in Patients with Heart Failure and Sinus Rhythm. **2020**, 61, 1204-1211 0

- 341 Percutaneous Coronary Intervention in Diabetic Patients.
- 340 Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome. **2020**, 39, 493-501
- 339 Top studies relevant to primary care practice. **2018**, 64, 280-285 1
- 338 For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?. **2020**, 73, 58-61
- 337 Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States. **2020**, 13, 184-190
- 336 CHADS-VASc Score and Risk of New-Onset Peripheral Arterial Occlusive Disease in Patients without Atrial Fibrillation. **2021**, 37, 261-268
- 335 Reversal of anticoagulation in neurosurgical and neurocritical care settings. **2022**, 239-266
- 334 Risk factors and pharmacological therapy in patients with vascular disease. **2022**, 11-24
- 333 Ginkgo, Ginseng und Gerinnung. **2021**, 42, 301-311 1
- 332 Phenotypic Clustering of Patients With Newly Diagnosed Coronary Artery Disease Using Cardiovascular Magnetic Resonance and Coronary Computed Tomography Angiography. **2021**, 8, 760120 0
- 331 Antithrombotic therapy after 1 year of dual antiplatelet therapy following acute coronary syndrome: What to do?. **2021**,
- 330 Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. **2021**, 1
- 329 A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban.. **2022**, 28, e934341 1
- 328 Joint statement from the European Atherosclerosis Society and European Society of Vascular Medicine focuses on patients with peripheral arterial disease. **2021**, 1
- 327 Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk. **2021**, 22, 0
- 326 Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). **2021**, 6-59 1
- 325 Direct oral anticoagulants: A review for the non-specialist.. **2021**, 13, 9239
- 324 Incorporation of Fibrin, Platelets, and Red Blood Cells into a Coronary Thrombus in Time and Space. **2021**, 0

- 323 Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. **2021**, 22, 0
- 322 Unsupervised Learning for Automated Detection of Coronary Artery Disease Subgroups. **2021**, 10, e021976 2
- 321 Prinzipien der antithrombotischen Therapie bei arteriellen Erkrankungen. **2021**, 1-6
- 320 Progress in the Use of Anticoagulant Drugs in Elderly Patients. **2021**, 11, 5911-5916
- 319 Antithrombotika und Antihämorrhagika. **2021**, 299-326 0
- 318 Minding the gap - Heterogeneity of antithrombotic treatment preferences in complex scenarios in absence of evidence-based guidelines.. **2021**,
- 317 Chronisches Koronarsyndrom: Neudefinition der stabilen koronaren Herzerkrankung.
- 316 Koronare Herzkrankheit: Aktuelle Aspekte der Behandlung.
- 315 [Key aspects of drug therapy in vascular surgery].. **2021**, 27, 17-25
- 314 Novel Hemorrhagic Risk Score in Elderly Patients with Coronary Artery Disease and Gastrointestinal Malignant Tumor Comorbidity: A 10-year Clinical Inpatient Data Analysis from 2 Medical Centers. **2021**, 1, 163-172
- 313 Antithrombotic Therapy in the Prevention of Stroke.. **2021**, 9, 0
- 312 Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation.. **2022**, 0
- 311 Impact of peripheral artery disease on prognosis after percutaneous coronary intervention: Outcomes from the multicenter prospective e-ULTIMASTER registry.. **2022**, 0
- 310 Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardio-pulmonary Disease.. **2022**, 1
- 309 Long-term outcomes of coronary artery bypass graft surgery in patients with widespread atherosclerotic lesions of the coronary and peripheral vascular basins (based on the REGATA long-term antithrombotic therapy registry). **2022**, 11, 30-43
- 308 Aspirin for Primary and Secondary Prevention of Cardiovascular Disease: Time to Stop?. **2022**, 2
- 307 A Review of Antithrombotic Therapies for Patients with Chronic Peripheral Arterial Disease and after Revascularization.. **2022**, 33197211048596
- 306 Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel vs dual antiplatelet therapy in patients with atherosclerotic disease.. **2022**, 2

- 305 Targeted proteomics improves cardiovascular risk prediction in secondary prevention.. **2022**, 3
- 304 Traitement antithrombotique dans l'artériopathie oblitérante des membres inférieurs: pourquoi et pour qui?. **2022**, 2022, 3-8
- 303 Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.. **2022**, 28, 10760296211073922
- 302 Antiplatelet therapy in cardiovascular disease: current status and future directions.. **2022**, 3
- 301 Aspirin desensitization or biologics for aspirin-exacerbated respiratory disease - How to choose?. **2022**, 2
- 300 Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.. **2022**, 1
- 299 Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention.. **2022**, 29, 91 1
- 298 DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. **2021**, 36, 108101 2
- 297 Current management and screening of peripheral and coronary artery disease in people with diabetes mellitus in Europe. The PADDIA/CADDIA survey.. **2022**, 109214
- 296 Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. **2021**, 1
- 295 Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?. **2022**, 14, 100309
- 294 Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.. **2021**, 246, 44-44 0
- 293 Anticoagulation After Primary PCI: The Land of Promises and Uncertainty.. **2022**, 15, 264-267 1
- 292 Tendencias actuales en el tratamiento antitrombótico. **2022**, 0
- 291 Building your Peripheral Artery Disease Tool Kit: Medical Management of PAD in 2022.. **2022**, 1
- 290 The OAC-PAD Risk Score Predicts Major Bleeding Events one Year after Hospitalisation for Peripheral Artery Disease.. **2022**, 2
- 289 Contemporary Management of Stable Coronary Artery Disease.. **2022**, 1 0
- 288 Biomarqueurs en anesthésie. **2022**,

|     |  |    |
|-----|--|----|
| 287 | [What the (general and abdominal) surgeon should know about thrombosis prophylaxis].. <b>2022</b> , 1  |    |
| 286 | Effect of combining aspirin and rivaroxaban on atherosclerosis in mice.. <b>2022</b> , 345, 7-14   | 0  |
| 285 | Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.. <b>2022</b> ,  | 2  |
| 284 | The association of anticoagulation before admission and survival of patients with COVID-19.. <b>2021</b> ,   | 0  |
| 283 | Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa-PAR2-Mediated Autophagy Suppression.. <b>2021</b> , 6, 964-980                         | 1  |
| 282 | D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis.. <b>2021</b> , 19, 102                    | 0  |
| 281 | Treatment of a patient with multifocal atherosclerosis and severe aortic stenosis. <b>2021</b> , 16, 81  |    |
| 280 | Dual Pathway of Inhibition and Vascular Protection in Patients with Atherosclerotic Disease. <b>2021</b> , 280-300   |    |
| 279 | Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease.. <b>2022</b> , 27, 10742484221084772 |    |
| 278 | Chronisches Koronarsyndrom. <b>2022</b> , 1-21   |    |
| 277 | Recurrent vertebrobasilar strokes and transient-ischemic attacks with challenging workup: Case report.. <b>2022</b> , 8, 50-56   |    |
| 276 | Stable Ischemic Heart Disease. <b>2022</b> , 213-234   |    |
| 275 | Antithrombotic Therapy in Peripheral Arterial Disease:Risk Stratification and Clinical Decision Making.. <b>2022</b> ,   | 0  |
| 274 | Diagnosis and Treatment of Acute Coronary Syndromes: A Review.. <b>2022</b> , 327, 662-675   | 10 |
| 273 | A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes.. <b>2022</b> , 194, E205-E215  | 0  |
| 272 | State-of-the-art-mini review: Dual pathway inhibition to reduce arterial and venous thromboembolism.. <b>2022</b> ,  | 1  |
| 271 | When and How to Combine Antiplatelet and Anticoagulant Drugs?. <b>2022</b> , 42, 73-79   | 0  |
| 270 | The Anti-Coronavirus Therapy (ACT) trials: design, baseline characteristics, and challenges.. <b>2022</b> ,  | 1  |

|     |   |   |
|-----|---|---|
| 269 | Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.. <b>2022,</b>                                  |   |
| 268 | Management of atherosclerotic extracranial carotid artery stenosis.. <b>2022, 21, 273-283</b>   | 0 |
| 267 | Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.. <b>2022,</b>  | 5 |
| 266 | Escalation of Antithrombotic Therapy Should Be Considered in the Presence of Intraluminal Prosthetic Graft Thrombus Following Endovascular Aneurysm Repair.. <b>2022, 56, 1-5</b>   | 0 |
| 265 | The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases". <b>2022, 18, 56-66</b> |   |
| 264 | Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: A pharmacodynamic study of dual pathway inhibition versus dual antiplatelet therapy.. <b>2022,</b>   | 1 |
| 263 | [Predicting major bleeding events in patients with peripheral arterial disease: the OAC-PAD risk score].. <b>2022, 1-4</b>  | 0 |
| 262 | PRINCESS Without a Crown—The Challenge to Generate Evidence in the King’s Class of Vascular Surgery.. <b>2022,</b>  |   |
| 261 | Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities.. <b>2022,</b>   | 0 |
| 260 | Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism.. <b>2022,</b>  | 1 |
| 259 | Safety and Effectiveness of Endovascular Therapy for the Treatment of Peripheral Artery Disease in Patients with and without Diabetes Mellitus.. <b>2022, 33197221075857</b>  | 1 |
| 258 | Direct Oral Anticoagulants and Coronary Artery Disease.. <b>2022, ATVBHA121317171</b>   | 0 |
| 257 | Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.. <b>2022, 24, 277-293</b>  | 0 |
| 256 | L'essentiel des recommandations 2021 de la Société Européenne de cardiologie pour la prévention cardiovasculaire. Que faut-il retenir ?. <b>2022,</b>   |   |
| 255 | Preventing Left Ventricular Thrombus Formation: Another Reason to Use Very Low-Dose Rivaroxaban?. <b>2022,</b>  | 0 |
| 254 | Circulating Biomarkers in Lower Extremity Artery Disease.. <b>2022, 17, e09</b>   | 1 |
| 253 | Intracoronary Application of Super-Saturated Oxygen to Reduce Infarct Size Following Myocardial Infarction.. <b>2022, 11,</b>   | 1 |
| 252 | DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm.. <b>2022,</b>   |   |

251 In Reply to Struikmans et al.. **2022**, 112, 1289-1290

250 Antiplatelet therapy after percutaneous coronary intervention.. **2022**, 17, e1371-e1396

5

249 Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy.. **2022**, 148, 112772

2

248 Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.. **2022**,

0

247 A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.. **2022**, 14, eabj9625

3

246 Increased thrombogenicity is associated with revascularization outcomes in patients with chronic limb-threatening ischemia.. **2022**,

245 Efficacy and safety of direct oral anticoagulants with and without Aspirin: A systematic review and Meta-analysis.. **2022**, 40, 101016

0

244 Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients). **2021**, 5, e12618

0

243 Is There a Role for Direct Oral Anticoagulants in the Primary and Secondary Prevention of Myeloproliferative Neoplasm Associated Thrombosis?. **2021**, 2, 769-780

242 Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events.. **2021**, 1-21

0

241 Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases.. **2021**, 12, 794417

0

240 Peripheral Artery Disease: A comprehensive updated review.. **2021**, 101082

2

239 Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease.. **2021**, 8, 773214

1

238 Pleiotropic, Cellular Effects of Rivaroxaban on Autophagy Explain Atheroprotective Effects.. **2021**, 6, 981-983

0

237 Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm.. **2021**, 22, 962

2

236 Unexplained arterial thrombosis: approach to diagnosis and treatment. **2021**, 2021, 76-84

0

235 Acute and Long-Term Outcomes of ST-Elevation Myocardial Infarction in Cancer Patients, a 'Real World' Analysis with 175,000 Patients.. **2021**, 13,

0

234 Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial.. **2021**, 11, e048354

1

- 233 Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. **2021**, 0
- 232 Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach.. **2021**, 16, e48 0
- 231 Practical Importance of COMPASS Trial Results for Vascular Surgeons. **2020**, 233-244
- 230 Diagnosis and Management of Peripheral Artery Diseases. **2020**, 390-408 1
- 229 Chronic coronary syndromes in Europe: there is much room for improvement.. **2022**, 1
- 228 Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularisation.. **2021**,
- 227 The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study.. **2022**, 10, 0
- 226 Advances in Recurrent Stroke Prevention: Focus on Antithrombotic Therapies.. **2022**, 130, 1075-1094 1
- 225 A Comprehensive Review on Antithrombotic Therapy for Peripheral Artery Disease. **2022**, 35, 124-124 1
- 224 Direct Oral Anticoagulant Treatment Is Associated With a Lower Prevalence of Thin-Cap Fibroatheroma. **2022**,
- 223 Dual antiplatelet treatment for minor acute ischemic stroke and high-risk transient ischemic attack: have we reached the limit of antithrombotic management?. **2022**,
- 222 Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. **2022**, 1
- 221 Die polyvaskuläre Erkrankung Eine Übersicht über die Datenlage und Managementstrategien. **2022**, 11, 147-153
- 220 Table\_1.docx. **2019**,
- 219 Presentation\_1.pptx. **2020**,
- 218 Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review.. **2022**, 1358863X221091320 0
- 217 A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control.. **2021**, 20, 238 1
- 216 Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era.. **2020**, 5, 171-174



|     |  |    |
|-----|--|----|
| 215 | Antithrombotic Treatment of Stable Coronary Artery Disease. <b>2021</b> , 37, 574-579  |    |
| 214 | OUP accepted manuscript.   | 1  |
| 213 | [COMPASS study results as a foundation for new treatment approach for neurological patients. Opinion of the expert council of december 18, 2021].. <b>2022</b> , 122, 94-99            |    |
| 212 | Impact of pre-existing vascular disease on clinical outcomes in patients with non-ST-segment myocardial infarction: a nationwide cohort study.. <b>2022</b> ,                          |    |
| 211 | Qualitätssicherung im stationären Bereich. <b>2022</b> , 1-8   |    |
| 210 | Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines.. <b>2022</b> , 13, 878416   | 0  |
| 209 | 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. <b>2022</b> , 21, 3235   | 11 |
| 208 | Macrovascular Complications. <b>2022</b> ,   | 0  |
| 207 | How to optimize treatment in patients with different forms of coronary artery disease. <b>2022</b> , 273-279   |    |
| 206 | High risk of early and late cardiovascular events after endovascular aortic aneurysm repair.. <b>2022</b> ,  |    |
| 205 | European Stroke Organisation (ESO) Guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. 239698732211000 | 5  |
| 204 | Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke.. <b>2022</b> ,         | 2  |
| 203 | . <b>2022</b> , 194, E620-E631   |    |
| 202 | Antithrombotische Therapie bei Diabetes mellitus.  |    |
| 201 | Antithrombotic Strategies in Endovascular Interventions. <b>2022</b> , 830-834   |    |
| 200 | Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention?. <b>2022</b> ,  | 0  |
| 199 | Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease. <b>2022</b> , 407-419   |    |
| 198 | Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.. <b>2022</b> , 79, 1660-1671                                      | 7  |

|     |   |   |
|-----|---|---|
| 197 | Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study. <b>2022</b> , 9,                | 1 |
| 196 | Coagulation factors XI and XII as possible targets for anticoagulant therapy.. <b>2022</b> , 214, 53-62   | 0 |
| 195 | The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice.. <b>2022</b> , 1-13   |   |
| 194 | Clinical experience with dual pathway inhibition therapy: case series and mini review.  |   |
| 193 | Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.  | 2 |
| 192 | Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. <b>2022</b> , 9, 17-26   |   |
| 191 | Peripheral Arterial Disease in Patients With Acute Coronary Syndrome: Results From a Large Real-World Registry. <b>2022</b> ,   |   |
| 190 | Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. | 1 |
| 189 | Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.   | 0 |
| 188 | European society for vascular surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease. <b>2022</b> ,             | 4 |
| 187 | Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants.  | 2 |
| 186 | Conduit selection and early graft failure in coronary artery bypass surgery: a post hoc analysis of the COMPASS CABG study. <b>2022</b> ,   | 1 |
| 185 | Urinary Fatty Acid Binding Protein 3 Has Prognostic Value in Peripheral Artery Disease. 9,  | 0 |
| 184 | Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease. 13,  |   |
| 183 | P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.  | 5 |
| 182 | P2Y12 Inhibitor Monotherapy is Associated with Superior Outcomes as Compared to Aspirin Monotherapy in Chronic Limb Threatening Ischemia. <b>2022</b> ,                             | 0 |
| 181 | Grundlagen des perioperativen Umgangs mit direkten oralen Antikoagulanzen.  |   |
| 180 | Management des akuten Koronarsyndroms ohne ST-Strecken-Hebung.  |   |

- 179 Urinary Cystatin C Has Prognostic Value in Peripheral Artery Disease. **2022**, 12, 860 ○
- 178 Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study. **2022**, 11, 3554
- 177 Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. **2022**, 5, e2215580 ○
- 176 Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance.
- 175 Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. **2022**, 145, 1875-1877 ○
- 174 Potential Reduction in Adverse Events and Cost with Novel Anticoagulants among Patients with Acute Limb Ischemia. **2022**, 2022, 1-6
- 173 Peripheral arterial disease (pathophysiology, presentation, prevention/management). **2022**, 361-375
- 172 The association between prothrombin time-international normalized ratio and long-term mortality in patients with coronary artery disease: a large cohort retrospective study with 44,662 patients. **2022**, 22, ○
- 171 (Is it time to replace acetylsalicylic acid monotherapy in secondary prevention with a more effective treatment?). **2022**, 64, 305-309
- 170 The Frequency of Primary Healthcare Contacts Preceding the Diagnosis of Lower-Extremity Arterial Disease: Do Women Consult General Practice Differently?. **2022**, 11, 3666 ○
- 169 A System-Wide Investigation and Stratification of the Hemostatic Proteome in Premature Myocardial Infarction. 9,
- 168 Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ○
- 167 Diagnosis and Management of Heart Disease. **2022**, 139-172
- 166 EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. **2022**, 6, e750 ○
- 165 Resumption of Antiplatelet Therapy after Major Bleeding.
- 164 Percutaneous coronary intervention with peripheral artery disease in the contemporary era: Still life or limb?. **2022**,
- 163 Critical Limb Ischemia: Update for the Cardiovascular Anesthesiologist. **2022**, ○
- 162 Cardiovascular Complications After Noncardiac Surgery: New Insights in Surveillance and Management. **2022**, 100276

- 161 Evaluation of Subclinical Vascular Disease in Diabetic Kidney Disease: A Tool for Personalization of Management of a High-Risk Population. **2022**, 12, 1139 1
- 160 The impact of type 2 immunity and allergic diseases in atherosclerosis. 2
- 159 High Rates of Recurrent Revascularization in Acute Limb Ischemia in National Surgical Quality Improvement Program Study. **2022**, 1
- 158 Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. **2022**, 06, e177-e183
- 157 Effect of Direct Oral Anticoagulants versus Warfarin on Patency in High-Risk Bypass Patients. **2022**,
- 156 Focus on optimizing treatment of coronary heart disease.
- 155 Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
- 154 Low-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum. **2022**, 7, 64-69
- 153 Antiplatelet agents and anticoagulants for hypertension. **2022**, 2022, 1
- 152 Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry. 0
- 151 Potent antithrombotic treatments in Asian vs. non-Asian patients. 0
- 150 Managing thrombotic risk in patients with diabetes. **2022**, 21, 0
- 149 Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases. 0
- 148 Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease. 9, 0
- 147 Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. **2022**, 3
- 146 Cancer-related stroke: Exploring personalized therapy strategies. 0
- 145 Diabetes und kardiovaskuläre Ereignisse. **2022**, 20, 223-228
- 144 The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial. 0

|     |   |   |
|-----|---|---|
| 143 | Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices. <b>2022</b> , 3, e222419  | 1 |
| 142 | INTERBLEED: Design of an international study of risk factors for gastrointestinal bleeding and cardiovascular events after gastrointestinal bleeding. <b>2022</b> ,   |   |
| 141 | Approaches to Peripheral Artery Disease in Diabetes: Are There Any Differences?. <b>2022</b> , 19, 9801   | 4 |
| 140 | Antiplatelet therapy after acute ischemic stroke or transient ischemic attack.  |   |
| 139 | Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions.  | 4 |
| 138 | Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. <b>2022</b> , 31, 106742                 | 3 |
| 137 | A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction.        | 4 |
| 136 | Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population.   | 0 |
| 135 | Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. <b>2022</b> , 23, 11317  | 0 |
| 134 | A Decade On: The Evolving Renaissance in Intracranial Atherosclerotic Disease.  | 0 |
| 133 | Additional prognostic value of stress cardiovascular magnetic resonance for cardiovascular risk stratification after a cryptogenic ischemic stroke. 9,  | 0 |
| 132 | Prevalence and risk of inappropriate dosing of direct oral anticoagulants in two Swiss atrial fibrillation registries. <b>2022</b> , 107120   | 0 |
| 131 | Left main coronary disease: evolving management concepts.   | 0 |
| 130 | Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients without Atrial Fibrillation? Evidence from Randomized Clinical Trials. <b>2022</b> ,  | 0 |
| 129 | Variability in Antithrombotic Therapy After Infrainguinal Lower Extremity Bypass. <b>2022</b> ,   | 0 |
| 128 | Outcomes Associated with 50 mg/d and 100 mg/d Aspirin for the Prevention and Management of Cardiovascular Disease in Chinese Elderly: Single-Center Interim Analysis of a Multicenter, Prospective, Observational Study. Volume 15, 7089-7100 | 0 |
| 127 | Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1. <b>2022</b> , 23, 10203  | 0 |
| 126 | Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. <b>2022</b> , 387, 978-988   | 5 |

|     |  |   |
|-----|--|---|
| 125 | Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. <b>2022</b> , 400, 997-1007 | 5 |
| 124 | Emerging roles of Protease-Activated Receptors in Cardiometabolic Disorders. <b>2022</b> ,   | 0 |
| 123 | Impact of psychological status on cardiovascular diseases: Is it time for upgrading risk score charts?. <b>2022</b> , 359, 42-43   | 0 |
| 122 | Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction. <b>2022</b> , 47, 101398  | 0 |
| 121 | Putting It All Together: An Algorithmic Approach to Treat Patients with Peripheral Arterial Disease. <b>2022</b> , 319-327   | 0 |
| 120 | Pharmacologic Interventions in Patients with Peripheral Arterial Disease. <b>2022</b> , 67-79  | 0 |
| 119 | Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study. <b>2022</b> , 19, 147916412211298                          | 0 |
| 118 | Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention. <b>2022</b> , 11, 40-50   | 0 |
| 117 | Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry. | 0 |
| 116 | Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. <b>2022</b> ,                                      | 0 |
| 115 | Antithrombotic therapy in peripheral arterial disease. 9,  | 0 |
| 114 | Factor XI inhibitors: cardiovascular perspectives.   | 2 |
| 113 | Advancing Peripheral Artery Disease Quality of Care and Outcomes Through Patient-Reported Health Status Assessment: A Scientific Statement From the American Heart Association.                                    | 0 |
| 112 | Clustering of patients with inconclusive non-invasive stress testing referred for vasodilator stress cardiovascular magnetic resonance. <b>2022</b> ,  | 0 |
| 111 | Platelets and Their Role in Hemostasis and Thrombosis From Physiology to Pathophysiology and Therapeutic Implications. <b>2022</b> , 23, 12772   | 2 |
| 110 | Kidney function and the comparative effectiveness and safety of direct oral anticoagulants versus warfarin in adults with atrial fibrillation: a multicenter observational study.                                  | 0 |
| 109 | Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. <b>2022</b> , 22, 789-802   | 0 |
| 108 | Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. <b>2022</b> , 100513   | 0 |

|     |   |   |
|-----|---|---|
| 107 | Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials. <b>2022</b> ,   | 0 |
| 106 | Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population. <b>2022</b> , 21,   | 0 |
| 105 | Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. <b>2022</b> ,   | 0 |
| 104 | Outcomes After Receipt of Neuraxial or Regional Anesthesia Instead of General Anesthesia for Lower Limb Revascularization Surgery: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies. <b>2022</b> ,  | 0 |
| 103 | Long-term Management of Patients with Myocardial Infarction: An Updated Review. Publish Ahead of Print,   | 0 |
| 102 | Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. <b>2022</b> , 80, 1735-1747  | 0 |
| 101 | Sodium ferulate-functionalized silver nanopyramides with synergistic antithrombotic activity for thromboprophylaxis. <b>2022</b> , 220, 112925  | 0 |
| 100 | Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP [A narrative review. <b>2022</b> , 43, 101132  | 0 |
| 99  | Antithrombotic Resumption after Acute Upper Gastrointestinal Bleeding [Authors]Reply. <b>2017</b> , 47, 397-397   | 0 |
| 98  | Thoughts on secondary prevention after percutaneous coronary intervention in Japan. <b>2018</b> , 4, 67-70  | 0 |
| 97  | Endothelial cell dysfunction: Implications for the pathogenesis of peripheral artery disease. 9,  | 1 |
| 96  | Defining Preventive Cardiology: A Clinical Practice Statement from the American Society for Preventive Cardiology. <b>2022</b> , 100432   | 2 |
| 95  | The impact of direct oral anticoagulants on viscoelastic testing [A systematic review. 9,   | 0 |
| 94  | High Plasma Levels of Activated Factor VII-Antithrombin Complex Point to Increased Tissue Factor Expression in Patients with SARS-CoV-2 Pneumonia: A Potential Link with COVID-19 Prothrombotic Diathesis. <b>2022</b> , 12, 2792 | 1 |
| 93  | The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices.  | 0 |
| 92  | Effect of direct oral anticoagulants in patients with atrial fibrillation with mitral or aortic stenosis: A review. 9,  | 0 |
| 91  | Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment. <b>2022</b> , 9, 397  | 0 |
| 90  | Pathophysiological mechanisms of thrombosis in acute and long COVID-19. 13,   | 0 |

- 89 The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats. ○
- 88 Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. **2022**, 39, 364-372 ○
- 87 Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. **2022**, ○
- 86 Integrating Mechanisms in Thrombotic Peripheral Arterial Disease. **2022**, 15, 1428 ○
- 85 Thromboembolism Induced by Mycoplasma Pneumoniae in Children: A Case Report and Literature Review. **2022**, 12, 10489-10496 ○
- 84 PCI Should Be the First Option for All Left Main Disease? An Interventional Cardiologist's Perspective. **2022**, 47-63 ○
- 83 Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry. 64, ○
- 82 The use of acetylsalicylic acid for prevention of cardiovascular complications in patients undergoing COVID-19. A review of current recommendations. **2022**, 15, 656 ○
- 81 Revisiting secondary prevention in coronary heart disease. **2022**, 74, 431-440 ○
- 80 Rationale and Design of LAPIS: A Multicenter Prospective Cohort Study to Investigate the Efficacy and Safety of Low-Dose Aspirin in Elderly Chinese Patients. Volume 15, 8333-8341 ○
- 79 Angina in 2022: Current Perspectives. **2022**, 11, 6891 ○
- 78 Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events. **2022**, 5, e2243201 1
- 77 Antithrombotisches Management nach akutem oder chronischem Koronarsyndrom. **2022**, 11, 555-559 ○
- 76 Antithrombotische Therapie bei pAVK und Aortenerkrankungen. **2022**, 11, 560-564 ○
- 75 Combination of antiplatelet and anticoagulant therapy, component network meta-analysis of randomized controlled trials. 9, 1
- 74 Long-term outcomes of extended DAPT in a real-life cohort of consecutive STEMI patients. **2022**, ○
- 73 Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice Insights From the CANHEART Study. **2022**, 11, ○
- 72 Acetylsalicylic Acid Primus Inter Pares in Pharmacology. **2022**, 27, 8412 ○



|    |   |   |
|----|---|---|
| 71 | Visceral adipose tissue quantity and dysfunction and the occurrence of major bleeding in patients with established cardiovascular disease. <b>2022</b> ,                          | ○ |
| 70 | Acute, periprocedural and longterm antithrombotic therapy in older adults.  | ○ |
| 69 | Outcomes associated with antithrombotic strategies in heart failure with reduced ejection fraction and sinus rhythm following acute ischemic stroke. 13,                          | ○ |
| 68 | The predictive value of four serum biomarkers for major adverse events in patients with small abdominal aortic aneurysm. <b>2022</b> ,  | ○ |
| 67 | Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications. 1-12  | ○ |
| 66 | Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF- $\beta$ driven fibrotic remodeling in ischemic heart failure.   | ○ |
| 65 | Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease. <b>2022</b> , 11, 7440                                 | ○ |
| 64 | Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta-analysis. 13, | ○ |
| 63 | Blood coagulation disorders in heart failure: from basic science to clinical perspectives. <b>2023</b> ,  | ○ |
| 62 | Efficacy and safety outcomes of long-term anti-thrombotic treatment of chronic coronary artery disease: A systematic review and network meta-analysis. 9,                         | ○ |
| 61 | Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1. <b>2023</b> , 1-65  | ○ |
| 60 | The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes.  | ○ |
| 59 | Dual pathway inhibition of coagulation and inflammation with rivaroxaban: a new therapy paradigm against atherosclerosis. <b>2023</b> , Publish Ahead of Print,                   | ○ |
| 58 | Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?. <b>2023</b> , 12,  | ○ |
| 57 | Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI. <b>2023</b> , 16, 1-18                                 | 2 |
| 56 | Total Events and Net Clinical Benefit of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial. <b>2023</b> ,                 | ○ |
| 55 | Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials. 9,  | ○ |
| 54 | DUAL PATHWAY INHIBITION WITH RIVAROXABAN AND ASPIRIN REDUCES INFLAMMATORY BIOMARKERS IN ATHEROSCLEROSIS.. <b>2022</b> , Publish Ahead of Print,                                   | ○ |

|    |   |   |
|----|---|---|
| 53 | Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. <b>2023</b> , 24, 77-86  | 1 |
| 52 | Cardiovascular Disease Management in the Context of Global Crisis. <b>2023</b> , 20, 689  | 3 |
| 51 | Bleeding Risk in Patients with Peripheral Arterial Disease. <b>2023</b> , 13, 47  | 0 |
| 50 | Markers of coagulation and inflammation and adverse events in patients with active cancer and atherosclerosis: common features and differences. <b>2023</b> , 12, 64-78   | 0 |
| 49 | Peri-Interventional Triple Therapy with Dabigatran Modifies Vasomotion after Bare-Metal Stent Implantation in a Pig Coronary Artery Model. <b>2023</b> , 13, 280  | 0 |
| 48 | Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments. 1-3  | 0 |
| 47 | Use of Thromboelastography with Platelet Mapping to Identify Prothrombotic Coagulation Profiles in Patients with History of Cardiac Intervention Undergoing Lower Extremity Revascularization. <b>2023</b> , 236, 495-504 | 0 |
| 46 | Hemostatic abnormalities associated with diabetes and their clinical implications. <b>2023</b> , 199-220  | 0 |
| 45 | Pharmacology and Clinical Development of Factor XI Inhibitors. <b>2023</b> , 147, 897-913   | 1 |
| 44 | Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale.  | 0 |
| 43 | The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. <b>2023</b> , 372, 41-47   | 0 |
| 42 | Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <b>2023</b> , 24, 453-471  | 0 |
| 41 | The challenge of managing patients with coronary and peripheral arterial disease - The ridge walk between bleeding and ischaemia. <b>2023</b> , 376, 24-25  | 0 |
| 40 | Exploring phenotypes of deep vein thrombosis in relation to clinical outcomes beyond recurrence. <b>2023</b> ,  | 0 |
| 39 | Antithrombotische Therapie. <b>2022</b> , 233-263   | 0 |
| 38 | A hybrid automated event adjudication system for clinical trials. <b>2023</b> , 20, 166-175   | 0 |
| 37 | Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients with Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis. <b>2023</b> , 10, 65             | 0 |
| 36 | Chinese expert consensus on antithrombotic management of high-risk elderly patients with chronic coronary syndrome. <b>2023</b> , 6, 4-24   | 0 |

- 35 The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence. **2023**, 55, 449-463 ○
- 34 Atrial fibrillation in UK South Asian hospitalized ischemic stroke patients: The BRAINS study. **2023**, 18, e0281014 ○
- 33 Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome. **2023**, 6, e2255709 ○
- 32 Rivaroxaban for Patients With Acute Coronary Syndromes—Where Do We Stand?. **2023**, 6, e2255724 ○
- 31 Clinical Evaluation of Factor XIa Inhibitor Drugs. **2023**, 81, 771-779 ○
- 30 Peri- und postoperative medikamentöse Therapie. **2022**, 1-5 ○
- 29 Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. ○
- 28 Pronóstico a largo plazo de la extensión de la TAPD en una cohorte consecutiva de pacientes con IAMCEST. **2023**, ○
- 27 Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. ○
- 26 Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach. ○
- 25 Secondary Ischemic Stroke Prevention. ○
- 24 Angiographic Outcomes for Arterial and Venous Conduits Used in CABG. **2023**, 12, 2022 ○
- 23 Real-World Racial Variation in Treatment and Outcomes Among Patients with Peripheral Artery Disease. **2023**, 40, 1850-1866 ○
- 22 Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands. ○
- 21 Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. **2023**, 12, 2161 ○
- 20 Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation. **2023**, 176, ○
- 19 Association between High Bleeding Risk and 2-Year Mortality in Patients with Chronic Limb-Threatening Ischemia. **2023**, ○
- 18 Evidenzbasierte antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). ○

- 17 Antithrombotics and Gastrointestinal Prophylaxis: A Systematic Review. Publish Ahead of Print, ○
- 16 Adherence to cardiovascular prevention guidelines in an academic center. **2023**, ○
- 15 Current concepts and novel targets for antiplatelet therapy. ○
- 14 Evolving Diagnostic and Management Advances in Coronary Heart Disease. **2023**, 13, 951 ○
- 13 Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation. **2023**, ○
- 12 Association of CHA2DS2-VASc and HAS-BLED to Frailty and Frail Outcomes: From the TREAT-AF Study. **2023**, ○
- 11 Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. **2023**, 10, 164 ○
- 10 Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review. **2023**, 12, 2833 ○
- 9 There is no single gold standard study design (RCTs are not the gold standard). 1-4 ○
- 8 Symptomatic peripheral arterial disease: Aspirin simply is not enough. **2023**, 11, 675 ○
- 7 Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. 1-18 ○
- 6 Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach. 15, 142-153 ○
- 5 Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort. ○
- 4 Anticoagulation in type 2 myocardial infarctions: Lessons learned from the rivaroxaban in type 2 myocardial infarctions feasibility trial. **2023**, 101143 ○
- 3 Is the COMPASS pointing towards clinical equipoise for the right internal mammary artery?. ○
- 2 Optimal Medical Management in Patients undergoing Peripheral Vascular Interventions for Chronic Limb Threatening Ischemia is associated with Improved Outcomes. **2023**, ○
- 1 Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease. ○